

ИНФОРМАЦИЯ ЗА:
Наименование на заболяването
Мултисистемна атрофия
Определение на заболяването
Мултисистемната атрофия в невродегенеративно заболяване, характеризиращо се с автономна недостатъчност (кардиална и/или уринарна), паркинсонизъм, церебеларни нарушения и пирамидни белези със средна продължителност 6-9 години.
Четирицифрен код на заболяването по МКБ-10 (ако такъв е наличен)
G90.3
Код на заболяването по Orpha code
ORPHA102
Епидемиологични данни за заболяването в Република България
Предполага се болестност около 1/50,000-1/20,000 подобно на останалите страни в Европа.
В т.ч. научни публикации от последните пет години и приложена библиографска справка
<ol style="list-style-type: none"> 1. The Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. <i>New Eng. J. Med.</i> 369: 233-244, 2013. Note: Erratum: <i>New Eng. J. Med.</i> 371: 94 only, 2014. 2. Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Durr, A., Fowler, C. J., Kaufmann, H., Klockgether, T., Lees, A., Poewe, W., Quinn, N., Revesz, T., Robertson, D., Sandroni, P., Seppi, K., Vidailhet, M. Second consensus statement on the diagnosis of multiple system atrophy. <i>Neurology</i> 71: 670-676, 2008. 3. Fanciulli A, Wenning GK. Multiple-system atrophy. <i>N Engl J Med.</i> 2015, 2;372(14):1375-6. 4. Vanacore N, Bonifati V, Fabbrini G, Colosimo C, De Michele G, Marconi R, et al. Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. <i>Neurol Sci.</i> 2001 Feb. 22(1):97-9.
Епидемиологични данни за заболяването в Европейския съюз
3,4-4,9/100 000. МСА-паркинсонизъм подтипът преобладава в западното полукълбо, докато МСА-церебеларната подформа преобладава в източното полукълбо. Двата пола са еднакво представени.
В т.ч. научни публикации от последните пет години и приложена библиографска справка
<ol style="list-style-type: none"> 1. The Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. <i>New Eng. J. Med.</i> 369: 233-244, 2013. Note: Erratum: <i>New Eng. J. Med.</i> 371: 94 only, 2014.

2. Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Durr, A., Fowler, C. J., Kaufmann, H., Klockgether, T., Lees, A., Poewe, W., Quinn, N., Revesz, T., Robertson, D., Sandroni, P., Seppi, K., Vidailhet, M. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology* 71: 670-676, 2008.
3. Fanciulli A, Wenning GK. Multiple-system atrophy. *N Engl J Med.* 2015, 2;372(14):1375-6.
4. Vanacore N, Bonifati V, Fabbrini G, Colosimo C, De Michele G, Marconi R, et al. Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. *Neurol Sci.* 2001 Feb. 22(1):97-9.

Оценка на съответствието на заболяването с дефиницията за рядко заболяване съгласно § 1, т. 42 от допълнителните разпоредби на Закона за здравето

Заболяването е с разпространение под 5 на 10 000 души от населението на Европейския съюз.

Критерии за диагностициране на заболяването

Диагностициране на заболяването (дефиниция на случай): Диагнозата „вероятна“ МСА изисква наличието на паркинсонизъм с лош отговор на леводопа терапия или церебеларни нарушения в съчетание с тежки автономни нарушения (необяснима уринарна инконтиненция или спадане на кръвното налягане при изправяне с поне 30 mm Hg систола или 15 mm Hg диастола). МРТ белези, включващи атрофия на путамен и средно малкомозъчно краче. При [18F]-fluorodeoxyglucose PET се установява хипометаболизъм на путамен и церебелум. „Дефинитивна“ МСА изисква патоанатомично верифициране на α -синуклеин позитивни глиални цитоплазмени включвания с невродегенерация на стриатунигралните и оливодеребеларните структури.

Признаците и симптомите на заболяването: МСА е с начало в зряла възраст над 30 години, обичайно в диапазона от 55 до 60 години. Клиничните манифестации включват (ортостатична хипотония, синкоп), респираторни нарушения, сънна апнея, стридор и inspiratory sighs), констипация, мехурни нарушения (ранна уринарна инконтиненция, еректилна дисфункция при мъжете и Raynaud синдром). При някои случаи се наблюдават също и пирамидни белези (генерализирана хиперрефлексия и положителен Бабински).

МСА-паркинсонизъм е форма на МСА с преобладаващи паркинсонови белези с брадикинезия, ригидност, нерегулярен миклоничен постурален тремор и абнормна поза (каптокормия, Пиза синдром и диспропорционално антероколи). Някои пациенти с МСА-паркинсонизъм развиват също леводопа-индуцирани орофациална и краниоцервикална дистония. Класически тремор в покой не е често наблюдаван.

МСА-церебеларна форма е форма на МСА с преобладаващо церебеларно засягане с динамична и локомоторна атаксия, окуломоторна дисфункция и дизартрия.

Преобладаващите моторни черти могат да се променят във времето и пациентите с церебеларна атаксия могат да развият тежък паркинсонизъм, който да преобладава в клиничната картина.

При МСА може също да се наблюдават невропсихиатрични нарушения, окуломоторни нарушения и нарушения в съня като апатия, тревожност, депресия, REM-behavior disorder и периодични движения в крайниците по време на сън.

Етиологията и патогенезата: Етиологията на МСА е неизвестна, но наличието на цитоплазмени натрупвания на α -синуклеин, предимно в олигодендроглията, в

комбинация с невродегенерация в стриатонигралните и оливопонтocereбралните структури са патологични отличителен маркер на заболяването. Мутации в COQ2 (4q21.23) (кодиращ ензим, участващ в биосинтеза на коензим Q10) са били установени в множество фамилии с МСА, докато някои варианти се асоциират с повишен риск от спорадична МСА.

В т.ч. научни публикации от последните пет години и приложена библиографска справка

1. Gilman, S., Low, P., Quinn, N., Albanese, A., Ben-Shlomo, Y., Fowler, C., Kaufmann, H., Klockgether, T., Lang, A., Lantos, P., Litvan, I., Mathias, C., Oliver, E., Robertson, D., Schatz, I., Wenning, G. Consensus statement on the diagnosis of multiple system atrophy. Clin. Auton. Res. 8: 359-362, 1998.
2. Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Durr, A., Fowler, C. J., Kaufmann, H., Klockgether, T., Lees, A., Poewe, W., Quinn, N., Revesz, T., Robertson, D., Sandroni, P., Seppi, K., Vidailhet, M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71: 670-676, 2008.
3. Scholz, S. W., Houlden, H., Schulte, C., Sharma, M., Li, A., Berg, D., Melchers, A., Paudel, R., Gibbs, J. R., Simon-Sanchez, J., Paisan-Ruiz, C., Bras, J., and 26 others. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 65: 610-614, 2009. Note: Erratum: Ann. Neurol. 67: 277 only, 2010.

Алгоритми за диагностициране на заболяването

Алгоритми за диагностициране на заболяването: Диагнозата „вероятна“ МСА изисква наличието на паркинсонизъм с лош отговор на леводопа терапия или церебеларни нарушения в съчетание с тежки автономни нарушения (необяснима уринарна инконтиненция или спадане на кръвното налягане при изправяне с поне 30 mm Hg систола или 15 mm Hg диастола). МРТ белези, включващи атрофия на путамен и средно малкомозъчно краче. При [18F]-fluorodeoxyglucose PET се установява хипометаболизъм на путамен и церебелум. „Дефинитивна“ МСА изисква патоанатомично верифициране на α -синуклеин позитивни глиални цитоплазмени включвания с невродегенерация на стриатунигралните и оливоцеребеларните структури.

Признаците и симптомите на заболяването: МСА е с начало в зряла възраст над 30 години, обичайно в диапазона от 55 до 60 години. Клиничните манифестации включват (ортостатична хипотония, синкоп), респираторни нарушения, сънна апнея, стридор и inspiratory sighs), констипация, мехурни нарушения (ранна уринарна инконтиненция, ерекtilна дисфункция при мъжете и Raunaud синдром). При някои случаи се наблюдават също пирамидни белези (генерализирана хиперрефлексия и положителен Бабински).

МСА-паркинсонизъм е форма на МСА с преобладаващи паркинсонови белези с брадикинезия, ригидност, нерегулярен миклоничен постурален тремор и абнормна поза (каптокормия, Пиза синдром и диспропорционално антероколи). Някои пациенти с МСА-паркинсонизъм развиват също леводопа-индуцирани орофациална и краниоцервикална дистония. Класически тремор в покой не е често наблюдаван.

МСА-церебеларна форма е форма на МСА с преобладаващо церебеларно засягане с динамична и локомоторна атаксия, окуломоторна дисфункция и дизартрия.

Преобладаващите моторни черти могат да се променят във времето и пациентите с церебеларна атаксия могат да развият тежък паркинсонизъм, който да преобладава в

клиничната картина.

При МСА може също да се наблюдават невропсихиатрични нарушения, окуломоторни нарушения и нарушения в съня като апатия, тревожност, депресия, REM-behavior disorder и периодични движения в крайниците по време на сън.

Диференциалната диагноза на заболяването: При МСА-паркинсонизъм – Паркинсонова болест, други атипични паркинсонови заболявания (Прогресивна супрануклеарна парализа, Кортикобазална дегенерация). При МСА-церебеларна форма: наследствени спиноцеребеларни атаксия (СЦА 1,2,3,6 и 7), чуплива-Х-хромозома асоцииран тремор/атаксия синдром (FXTAS) и митохондриопатии (POLG1 гена мутация).

Лабораторни, образни и хистологични изследвания: МСА се характеризира патологично с дегенерация на стриатонигралните и опивопонтоцеребеларните структури и глиални цитоплазмени включвания, които се състоят от абнормно фосфорилиран alpha-синуклеин (SNCA) или tau (МАРТ).

Генетични изследвания и медико-генетично консултиране: МСА се появява спорадично, но са описани няколко фамилни случая. Мултисистемна атрофия-1 (MSA1) може да се причини от хетерозиготна, хомозиготна или комбинирана хетерозиготна мутация на COQ2 гена на хромозома 4q21c автозомно-рецесивно или автозомно-доминантно унаследяване.

В т.ч. научни публикации от последните пет години и приложена библиографска справка

1. Gilman, S., Low, P., Quinn, N., Albanese, A., Ben-Shlomo, Y., Fowler, C., Kaufmann, H., Klockgether, T., Lang, A., Lantos, P., Litvan, I., Mathias, C., Oliver, E., Robertson, D., Schatz, I., Wenning, G. Consensus statement on the diagnosis of multiple system atrophy. Clin. Auton. Res. 8: 359-362, 1998.
2. Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Durr, A., Fowler, C. J., Kaufmann, H., Klockgether, T., Lees, A., Poewe, W., Quinn, N., Revesz, T., Robertson, D., Sandroni, P., Seppi, K., Vidailhet, M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71: 670-676, 2008.
3. Scholz, S. W., Houlden, H., Schulte, C., Sharma, M., Li, A., Berg, D., Melchers, A., Paudel, R., Gibbs, J. R., Simon-Sanchez, J., Paisan-Ruiz, C., Bras, J., and 26 others. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 65: 610-614, 2009. Note: Erratum: Ann. Neurol. 67: 277 only, 2010.
4. Wullner, U., Abele, M., Schmitz-Heubsch, T., Wilhelm, K., Benecke, R., Deuschl, G., Klockgether, T. Probable multiple system atrophy in a German family. J. Neurol. Neurosurg. Psychiat. 75: 924-925, 2004.
5. Hara, K., Momose, Y., Tokiguchi, S., Shimohata, M., Terajima, K., Onodera, O., Kakita, A., Yamada, M., Takahashi, H., Hirasawa, M., Mizuno, Y., Ogata, K., Goto, J., Kanazawa, I., Nishizawa, M., Tsuji, S. Multiplex families with multiple system atrophy. Arch. Neurol. 64: 545-551, 2007.
6. The Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. New Eng. J. Med. 369: 233-244, 2013.

Алгоритми за лечение на заболяването

Алгоритми за лечение на заболяването: Съгласно Национален консенсус за диагностика и лечение на Паркинсоновата болест, а на когнитивните нарушения

съгласно Национален консенсус за ранна диагностика и лечение на болестта на Алцхаймер и други форми на деменция, както и съгласно международните критерии. Терапевтичните подходи към заболяването, в това число консервативни и оперативни, техните предимства, рискове и очаквана ефективност: Съобщава се временно подобрене на паркинсонизма при 20-30% от пациентите. Все още няма установена ефективна невропротективна терапия.

Препоръчителен диетичен режим и физическа активност и др.:

В т.ч. научни публикации от последните пет години и приложена библиографска справка

1. Национален консенсус за диагностика и лечение на Паркинсоновата болест, Двигателни заболявания, 2013, 10, 1.
2. Национален консенсус за ранна диагностика и лечение на болестта на Алцхаймер и други форми на деменция, април 2015.
3. Santiago Perez-Lloret, Olivier Flabeau, Pierre-Olivier Fernagut, Anne Pavy-Le Traon, María Verónica Rey, Alexandra Foubert-Samier, Francois Tison, Olivier Rascol, Wassilios G. Meissner. Current Concepts in the Treatment of Multiple System Atrophy. Movement Disorders Clinical Practice, 2015, 2, 1, 6-16.

Алгоритми за проследяване на заболяването

Алгоритми за проследяване на заболяването:

Прогнозата на заболяването: МСА е бързо прогресиращо заболяване с приковаване към инвалидна количка, неразбираема реч, интермитентна уринарна кататеризация, инвалидизираща ортостатична хипотония и когнитивен дефицит (дизекзекутивен синдром). Прогнозата е лоша със средна преживяемост от 6-9 години.

Възможни усложнения, Честота и тежест на усложненията и др: Бронхопневмония (48%) и внезапна смърт (21%) са най-честите терминални състояния при МСА. Уринарната дисфункция при МСА често води до инфекции на долния уринарен тракт, като повече от 50% от пациентите с МСА страдат от рецидивиращи инфекции на долния уринарен тракт и значителен брой умират от усложнения.

В т.ч. научни публикации от последните пет години и приложена библиографска справка

1. Papatsoris AG, Papapetropoulos S, Singer C, Deliveliotis C. Urinary and erectile dysfunction in multiple system atrophy (MSA). *Neurourol Urodyn.* 2008. 27(1):22-7.
2. Fanciulli A, Wenning GK. Multiple-system atrophy. *N Engl J Med.* 2015, 2;372(14):1375-6.

Алгоритми за рехабилитация на заболяването

Алгоритми за рехабилитация на заболяването: Съгласно Национален консенсус за диагностика и лечение на Паркинсоновата болест, Национален консенсус за ранна диагностика и лечение на болестта на Алцхаймер и други форми на деменция, както и съгласно международните критерии.

В т.ч. научни публикации от последните пет години и приложена библиографска справка

1. Национален консенсус за диагностика и лечение на Паркинсоновата болест, Двигателни заболявания, 2013, 10, 1.
2. Национален консенсус за ранна диагностика и лечение на болестта на Алцхаймер и други форми на деменция, април 2015.
3. Santiago Perez-Lloret, Olivier Flabeau, Pierre-Olivier Fernagut, Anne Pavy-Le Traon, María Verónica Rey, Alexandra Foubert-Samier, Francois Tison, Olivier

Rascol, Wassilios G. Meissner. Current Concepts in the Treatment of Multiple System Atrophy. Movement Disorders Clinical Practice, 2015, 2, 1, 6–16.

Необходими дейности за профилактика на заболяването (ако такива са приложими)

Дейности за профилактика на заболяването: Точната етиология на МСА-паркинсонизъм е все още неизвестна, но наличието на цитоплазмени агрегати от α -synuclein, предимно в олигодендроглия в комбинация с преобладаваща невродегенерация на стриатонигралните пътища са патологичен маркер на МСА-паркинсонов тип. Мутациите на COQ2 ген (4q21.23) (кодиращ ензима въввлечен в биосинтезата на коензим Q10) са наблюдавани множество фамилии с МСА, както и някои варианти на мутации, асоциирани с повишен риск от спорадичен МСА. Няма установени специфични профилактични мерки за заболяването.

В т.ч. научни публикации от последните пет години и приложена библиографска справка

1. Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Durr, A., Fowler, C. J., Kaufmann, H., Klockgether, T., Lees, A., Poewe, W., Quinn, N., Revesz, T., Robertson, D., Sandroni, P., Seppi, K., Vidailhet, M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71: 670-676, 2008.
2. Scholz, S. W., Houlden, H., Schulte, C., Sharma, M., Li, A., Berg, D., Melchers, A., Paudel, R., Gibbs, J. R., Simon-Sanchez, J., Paisan-Ruiz, C., Bras, J., and 26 others. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 65: 610-614, 2009. Note: Erratum: Ann. Neurol. 67: 277 only, 2010.

Предложения за организация на медицинското обслужване на пациентите и за финансиране на съответните дейности, съобразени с действащата в страната нормативна уредба

Създаването на Национален експертен център „Редки невродегенеративни заболявания, протичащи с когнитивни, поведенчески и моторни нарушения“ за диагностика, лечение и проследяване и рехабилитация включително и на пациенти с това заболявания под ръководството на чл.кор.проф.д-р Л. Трайков, дмн (национален експерт с най-голям опит и принос за диагностиката и лечението на тези заболявания).

Описание на опита с конкретни пациенти със съответното рядко заболяване (ако има такъв)

Опитът на кандидатстващия експертен център за диагноза и лечение на редки заболявания с атипичен паркинсонизъм, като мултисистемната атрофия датира от 2001 година със създаването на център за диагноза и лечение на невродегенеративни заболявания, протичащи с деменция и допълнително на център за диагноза и лечение на Паркинсонова болест. От дълги години този център е рефериран център за заболявания, протичащи с атипичен паркинсонизъм, като мултисистемната атрофия, особено за комплексни, редки и наследствени случаи. През годините вследствие на натрупания опит и труд, както и значителен брой на пациенти с тези редки заболявания, реферирани към нашите два центъра са осъществени няколко дисертации в областта: 1. Клинико-генетични корелации при невродегенеративни заболявания, протичащи с паркинсонизъм (защитена дисертация за доктор по медицина от д-р Радка Павлова, 2013 г., ръководител: чл.-кор. проф. Лъчезар Трайков), 2. Проучване на невропсихологичния профил при пациенти с Паркинсон плюс синдроми (защитена

дисертация за доктор по медицина от д-р Силвия Скелина, 2016 г., ръководител: чл.-кор. проф. Лъчезар Трайков) и 3. Клинико-генетични проучвания при фронтотемпорална деменция и сродни заболявания (защитена дисертация за доктор по медицински науки от д-р Шима Мехрабиан, 2016 г.). Събрана е база данни за отделни пациенти с отделни групи редки заболявания, с атипичен паркинсонизъм, като мултисистемната атрофия с подробно фенотипизиране на всеки един случай, което дава възможност за добър мониторинг на пациентите, както и изследователски анализ върху характеристиката на отделните заболявания. Дейността на центъра по отношение на диагноза и лечение на редки заболявания, с атипичен паркинсонизъм, като мултисистемната атрофия, обхваща всички диагностични дейности съобразно новите диагностични критерии на тези заболявания, включително допълнителни изследвания, които са нужни за диференциална диагноза на атипични/ранни/наследствени случаи, включващи изследвания за биомаркери, невроизобразяващи и генетични фактори. Центъра е член на the European Multisystem Atrophy Study Group и International Parkinson and Movement Disorder Society.

Публикации:

1. Petrova M, Pavlova R, Zhelev Y, Mehrabian S, Raycheva M, Traykov L. Investigation of neuropsychological characteristics of very mild and mild dementia with Lewy bodies. *J Clin Exp Neuropsychol*. 2015 Dec 17:1-7.
2. Petrova M, Mehrabian-Spasova S, Aarsland D, Raycheva M, Traykov L. Clinical and Neuropsychological Differences between Mild Parkinson's Disease Dementia and Dementia with Lewy Bodies. *Dement Geriatr Cogn Dis Extra*. 2015 May 29;5(2):212-20.
3. Петрова М., Трайков Л. Райчева М., Мехрабиан Ш., Желев Я., Масларов Д. Особености на когнитивния профил при Мултисистемна атрофия. *Българска Неврология*, 2007, 7(1), 33-36.
4. Скелина С, Павлова Р, Петрова М, Мехрабиан Ш, Григорова О, Трайков Л. Проучване на профила на когнитивни нарушения при пациенти с прогресивна супрануклеарна офталмопареза. *Българска неврология*, бр. 2, 2015
5. Павлова Р, Мехрабиан Ш, Скелина С, Желев Я, Михова К, Кънева Р, Митев В, Йорданова А, Трайков Л. Характеристика на дегенеративния паркинсонов синдром в зависимост от Аполипопротеин Е генотипа. *Неврология и психиатрия*, 4, 30-33, 2014;
6. Скелина С, Павлова Р, Петрова М, Райчева М, Трайков Л. Невропсихологичен профил и тежест на когнитивните нарушения при атипичните паркинсонови синдроми. *Българска неврология*, бр. 2, 2015.
7. R. Pavlova, K. Mihova, S. Mehrabian, M. Petrova, S. Skelina, R. Kaneva, V. Mitev,

L. Traykov. Novel LRRK2 6165C>G mutation in a patient with Parkinson's disease-dementia: a case report. In: JOINT CONGRESS OF EUROPEAN NEUROLOGY Istanbul, Turkey, May 31-June 3, 2014.

8. Pavlova R., K. Mihova, S. Mehrabian, M. Petrova, S. Skelina, R. Kaneva, A. Jordanova, V. Mitev, L. Traykov. LRRK2 mutation c.4536+3A>G in a patient with multiple system atrophy: a case report. In: JOINT CONGRESS OF EUROPEAN NEUROLOGY Istanbul, Turkey, May 31-June 3, 2014.

Consensus Report

Clinical Autonomic Research 1998, 8:359–362

We report the results of a consensus conference on the diagnosis of multiple system atrophy (MSA). We describe the clinical features of the disease, which include four domains: autonomic failure/urinary dysfunction, parkinsonism and cerebellar ataxia, and corticospinal dysfunction. We set criteria to define the relative importance of these features. The diagnosis of possible MSA requires one criterion plus two features from separate domains. The diagnosis of probable MSA requires the criterion for autonomic failure/urinary dysfunction plus poor levodopa responsive parkinsonism or cerebellar ataxia. The diagnosis of definite MSA requires pathological confirmation.

Keywords: multiple system atrophy, parkinsonism, cerebellar ataxia, autonomic insufficiency, urinary dysfunction, glial cytoplasmic inclusions.

Consensus statement on the diagnosis of multiple system atrophy

Sid Gilman, Phillip Low, Niall Quinn, Alberto Albanese, Yoav Ben-Shlomo, Clare Fowler, Horacio Kaufmann, Thomas Klockgether, Anthony Lang, Peter Lantos, Irene Litvan, Christopher Mathias, Eugene Oliver, David Robertson, Irwin Schatz, and Gregor Wenning*

Address correspondence to Dr. Sid Gilman, Professor & Chair, Department of Neurology, University of Michigan Medical Center, 1500 E. Medical Center Drive/1914 TC, Ann Arbor, MI 48109-0316, USA.
Tel: (734) 936-9070; Fax: (734) 763-5059
E-mail: sgilman@umich.edu

Received Mar 7, 1998; accepted July 13, 1998

Multiple system atrophy (MSA), a progressive neurodegenerative disease of undetermined etiology, occurs sporadically and causes parkinsonism and cerebellar, autonomic, urinary, and pyramidal dysfunction in many combinations [1–4]. The disease affects both sexes, usually beginning in middle age and progressing over intervals of 1 to 18 years, with a median survival of 9.3 years from the first symptom [5,6]. The parkinsonian features include bradykinesia with rigidity, postural instability, hypokinetic speech, and often tremor, usually with a poor or unsustained response to chronic levodopa therapy. The cerebellar dysfunction consists of ataxia of gait, limb movements and speech, and disorders of extraocular movements [7]. Autonomic insufficiency results in orthostatic hypotension, often with an inadequate heart rate response to standing, male erectile dysfunction (MED), constipation, and decreased sweating [8,9]. Urinary symptoms include urgency, frequency, nocturia, incomplete bladder emptying, and incontinence [10]. The diagnosis of MSA requires primarily clinical assessment; however, a number of laboratory tests may help to support the diagnosis.

The neuropathological changes consist of a high density of glial cytoplasmic inclusions (GCIs) in association with degenerative changes in some or all of the following structures: putamen, caudate nucleus, globus pallidus, substantia nigra, locus ceruleus, inferior olives, pontine nuclei, cerebellar Purkinje cells, autonomic nuclei of the brainstem, and the intermediolateral cell columns and Onuf's nucleus in the spinal cord [11,12]. GCIs are ubiquitin-, tau- and α -synuclein-positive oligodendroglial inclusions [12].

Some efforts have been made to establish diagnostic criteria [4], but no consistent detailed guidelines have been developed. Accordingly, a consensus conference was convened on April 23 and 24, 1998 in Minneapolis, Minnesota, cosponsored by the American Autonomic Society and the American Academy of Neurology. The goal of the conference was to develop guidelines for the diagnosis of MSA. We achieved consensus on the items listed below and shown in Tables 1, 2, and 3. These guidelines have not yet been validated, and will almost certainly require further modification in the light of future experience.

Clinical domains

Autonomic and urinary dysfunction

Orthostatic hypotension (OH) may indicate autonomic failure and can be asymptomatic or symptomatic. When symptomatic, it typically occurs after the onset of MED and urinary symptoms. Symptoms of OH result from cerebral hypoperfusion, and syncope may occur. The consensus conference determined that the clinical diagnosis of probable MSA requires a reduction of systolic blood pressure by at least 30 mm Hg or of diastolic blood pressure by at least 15 mm Hg within 3 minutes of standing from the recumbent

* Please see "Conference Participants" section at the end of this article for a full listing of author affiliations.

Table 1. Clinical domains, features, and criteria used in the diagnosis of MSA*

I. Autonomic and urinary dysfunction
A) Autonomic and urinary features
1. Orthostatic hypotension (by 20 mm Hg systolic or 10 mm Hg diastolic)
2. Urinary incontinence or incomplete bladder emptying
B) Criterion for autonomic failure or urinary dysfunction in MSA
Orthostatic fall in blood pressure (by 30 mm Hg systolic or 15 mm Hg diastolic) or urinary incontinence (persistent, involuntary partial or total bladder emptying, accompanied by erectile dysfunction in men) or both
II. Parkinsonism
A) Parkinsonian features
1. Bradykinesia (slowness of voluntary movement with progressive reduction in speed and amplitude during repetitive actions)
2. Rigidity
3. Postural instability (not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction)
4. Tremor (postural, resting, or both)
B) Criterion for parkinsonism in MSA
Bradykinesia plus at least one of items 2 to 4
III. Cerebellar dysfunction
A) Cerebellar features
1. Gait ataxia (wide based stance with steps of irregular length and direction)
2. Ataxic dysarthria
3. Limb ataxia
4. Sustained gaze-evoked nystagmus
B) Criterion for cerebellar dysfunction in MSA
Gait ataxia plus at least one of items 2 to 4
IV. Corticospinal tract dysfunction
A) Corticospinal tract features
1. Extensor plantar responses with hyperreflexia
B) Corticospinal tract dysfunction in MSA: no corticospinal tract features are used in defining the diagnosis of MSA

*A feature (A) is a characteristic of the disease and a criterion (B) is a defining feature or composite of features required for diagnosis.

position. Frequently this is accompanied by an inadequate increase in heart rate (less than 10 beats per minute). We note that this is a more pronounced degree of OH than established previously [4]. MED appears early and affects virtually all male patients with MSA, but the symptom has

Table 2. Diagnostic categories of MSA*

I. Possible MSA: One criterion plus two features from separate domains. When the criterion is parkinsonism, a poor levodopa response qualifies as one feature (hence only one additional feature is required).
II. Probable MSA: Criterion for: autonomic failure/urinary dysfunction plus poor levodopa-responsive parkinsonism or cerebellar dysfunction.
III. Definite MSA: Pathologically confirmed by the presence of a high density of glial cytoplasmic inclusions in association with a combination of degenerative changes in the nigrostriatal and olivopontocerebellar pathways.

*The features and criteria for each clinical domain are shown in Table 1.

Table 3. Exclusion criteria for the diagnosis of MSA

I. History
Symptomatic onset under 30 years of age
Family history of a similar disorder
Systemic diseases or other identifiable causes for features listed in Table 1
Hallucinations unrelated to medication
II. Physical examination
DSM criteria for dementia
Prominent slowing of vertical saccades or vertical supranuclear gaze palsy*
Evidence of focal cortical dysfunction such as aphasia, alien limb syndrome, and parietal dysfunction
III. Laboratory Investigation
Metabolic, molecular genetic, and imaging evidence of an alternative cause of features listed in Table 1

*In practice, MSA is most frequently confused with Parkinson's disease or progressive supranuclear palsy (PSP) [25]. Mild limitation of upward gaze alone is nonspecific, whereas a prominent (>50%) limitation of upward gaze or any limitation of downward gaze suggests PSP. Before the onset of vertical gaze limitation, a clinically obvious slowing of voluntary vertical saccades is usually easily detectable in PSP and assists in the early differentiation of these two disorders [26].

low specificity. Urinary frequency, urgency, incontinence, or incomplete bladder emptying also occur early and commonly.

Parkinsonism

The majority of MSA patients develop parkinsonian features at some stage of the disorder. All these patients have bradykinesia; rigidity, postural instability, and tremor also often occur. The tremor is usually irregular and postural, often incorporating myoclonus. A classical pill-rolling parkinsonian rest tremor is uncommon. The parkinsonism in MSA can be asymmetric. The dysarthria is mainly hypokinetic, often mixed with other components [13]. The parkinsonian features usually respond poorly to chronic levodopa therapy; however, up to 30% of patients show a clinically significant response to levodopa therapy at some time in the course, but the response is usually sustained for less than five years [5,14,15]. These are the most challenging patients for accurate diagnosis.

Cerebellar dysfunction

Ataxia of gait, the most common cerebellar feature of MSA, often occurs accompanied by dysarthria, limb ataxia, and sometimes gaze-evoked nystagmus and ocular dysmetria. A common finding is saccadic pursuit movements. The dysarthria in patients with predominantly cerebellar dysfunction is mainly ataxic, often mixed with other components [13].

Corticospinal dysfunction

Extensor plantar responses with hyperreflexia occur in about 50% of MSA patients. Corticospinal signs can contribute to the diagnosis, but are less important than abnormalities in the other domains.

Response to levodopa

Levodopa responsiveness should be tested by administering escalating doses (with a peripheral decarboxylase inhibitor) over a 3-month period up to at least 1 g per day (if necessary and if tolerated). A positive response is defined as clinically significant improvement. This should be demonstrated by objective evidence such as an improvement of 30% or more on part III (motor examination) of the Unified Parkinson's Disease Rating Scale [16].

Laboratory investigations

Autonomic function tests, sphincter electromyography (EMG), and neuroimaging may be used to support the diagnosis, and neuroimaging is helpful in excluding other conditions. The abnormalities described below have been defined principally in clinically well-established cases rather than in the early stages of the disease. In the early stages, the tests may give equivocal results. We consider it premature to incorporate laboratory results into the entirely clinical guidelines that we established, but envision the future development of "Laboratory Supported" diagnostic categories.

Assessment of autonomic function can be assisted by a comprehensive battery that evaluates the distribution and severity of sudomotor, cardiovagal, and sympathetic adrenergic deficits [17,18]. Autonomic function tests may help separate MSA from Parkinson's disease and from idiopathic cerebellar degenerations [8].

Sphincter EMG can be useful in the diagnosis of MSA. Analysis of individual motor unit potentials recorded from the external anal sphincter usually shows changes indicating chronic reinnervation, with markedly prolonged motor units [10,19].

Magnetic resonance imaging (MRI) can assist the evaluation by detecting abnormalities of striatum, cerebellum, and brainstem, but can be normal in up to 20% of cases [20]. Striatal abnormalities may include putaminal atrophy, slit-like signal change at the posterolateral putaminal margin, and hypointensity of the putamen relative to the globus pallidus [21]. Infratentorial abnormalities include cerebellar and pontine atrophy, and signal change in the pons and middle cerebellar peduncles [22]. Studies are in progress to evaluate the utility of magnetic resonance spectroscopy, positron emission tomography, and single photon emission tomography.

Diagnostic categories

We established three diagnostic categories reflecting differing levels of certainty: definite, probable, and possible. The diagnosis of definite MSA can only be made after neuropathological examination of the central nervous system revealing the characteristic density and distribution of GCIs and degenerative changes outlined above. The diagnosis of probable or possible MSA can be made using different combinations of

clinical domains, criteria, and features, as indicated in Tables 1 and 2. Exclusion criteria are shown in Table 3.

Terminology

MSA is a distinct clinicopathological entity. The term should not be used to describe other neurodegenerative diseases affecting multiple systems. The use of confusing terms such as "multisystem degeneration" for MSA is inappropriate and now should be discouraged. We recommend designating patients as having MSA-P if parkinsonian features predominate or MSA-C if cerebellar features predominate [23,24]. These terms are intended to replace the striatonigral degeneration (SND) and sporadic olivopontocerebellar atrophy (sOPCA) types of MSA, respectively. The term Shy Drager syndrome has been widely misused, and is no longer useful.

Acknowledgment

This conference was supported in part by the Office of Rare Diseases and the National Institute of Neurological Disorders and Stroke, National Institutes of Health; Glaxo Wellcome, Inc.; Hoechst Marion Roussel; and Roberts Pharmaceutical Corporation.

Conference participants

Sid Gilman, M.D., Department of Neurology, University of Michigan Medical Center, Ann Arbor, MI

Phillip Low, M.D., Department of Neurology, Mayo Clinic, Rochester, MN

Niall Quinn, M.D., and Clare Fowler, M.D., Department of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, England

Alberto Albanese, M.D., Department of Neurology, Università Cattolica, Istituto di Neurologia, Roma, Italy

Yoav Ben-Shlomo, M.D., Department of Social Medicine, Canynge Hall, Bristol, England

Horacio Kaufmann, M.D., Department of Neurology, Mt. Sinai Medical Center, New York, NY

Thomas Klockgether, M.D., Department of Neurology, University of Bonn, Bonn, Germany

Anthony Lang, M.D., Department of Neurology, Toronto Western Hospital, Toronto, Ontario, Canada

Peter Lantos, M.D., Ph.D., Department of Neuropathology, Institute of Psychiatry, London England

Irene Litvan, M.D., National Institutes of Health, Federal Building, Bethesda, MD

Christopher Mathias, D.Phil. D.Sc., Department of Neurovascular Medicine, Imperial College School of Medicine at St. Mary's, London, England, and Department of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, England

David Robertson, M.D., Departments of Pharmacology and Neurology, Vanderbilt University, Nashville, TN

Irwin Schatz, M.D., Department of Medicine, University of Hawaii at Manoa, Honolulu, HI

Gregor Wenning, M.D., Universitaets-Klinik fur Neurologie, Innsbruck, Austria

References

1. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. *J Neurol Neurosurg Psychiatr* 1969; 32:28-34.
2. Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, eds. *Movement disorders*. London: Butterworths, 1996; 262-281.
3. Albanese A, Colosimo C, Bentivoglio AR, et al. Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. *J Neurol Neurosurg Psychiatr* 1995; 59:144-151.
4. Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. *Neurology* 1996; 46:1470.
5. Wenning GK, Ben-Shlomo Y, Magalães M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. *Brain* 1994; 117:835-845.
6. Klockgether T, Lüdtke R, Kramer B, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. *Brain* 1998; 121:589-600.
7. Gilman S. Multiple System Atrophy. In: Jankovic J, Tolosa E, eds. *Parkinson's disease and movement disorders*, 3rd edition. Baltimore: Williams and Wilkins, 1998; 245-262.
8. Sandroni P, Ahlskog JE, Fealey RD, Low PA. Autonomic involvement in extrapyramidal and cerebellar disorders. *Clin Auton Res* 1991; 1:147-155.
9. Mathias CJ, Williams AC. The Shy Drager Syndrome (and Multiple System Atrophy). In: *Neurodegenerative diseases*. Calne DB, ed. Philadelphia: WB Saunders, 1994; 743-768.
10. Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. *J Urology* 1994; 151:1336-1341.
11. Daniel SE. The neuropathology and neurochemistry of multiple system atrophy. In: Bannister R, Mathias CJ, eds. *Autonomic failure: a textbook of clinical disorders of the autonomic nervous system*. Oxford: Oxford University Press; 1992:564-585.
12. Lantos PL. Multiple system atrophy. *Brain Pathology* 1997; 7:1293-1297.
13. Kluin KJ, Gilman S, Lohman M, Junck L. Characteristics of the dysarthria of multiple system atrophy. *Arch Neurol* 1996; 53:545-548.
14. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. *J Neurol Neurosurg Psychiatry* 1992; 55:1009-1013.
15. Parati EA, Fetoni V, Geminiani GC, et al. Response to L-DOPA in multiple system atrophy. *Clin Neuropharmacol* 1997; 16:139-144.
16. Fahn S, Elton R. Unified Parkinson's Disease Rating Scale Committee: Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, eds. *Recent developments in Parkinson's disease*. New York: Macmillan; 1987:153-164.
17. Mathias CJ, Bannister R. Investigation of Autonomic Disorders. In: *Autonomic failure. A textbook of clinical disorders of the autonomic nervous system*. 3rd edition. Bannister R, Mathias CJ, eds. Oxford: Oxford University Press; 1992:255-290.
18. Low PA. The composite autonomic scoring scale for the laboratory quantitation of generalized autonomic failure. *Mayo Clin Proc* 1993; 68:748-752.
19. Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. *Muscle Nerve* 1997; 20:1396-1403.
20. Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. *J Neurol Neurosurg Psychiatry* 1998; 65:65-71.
21. Lang AE, Curran T, Provias J, Bergeron C. Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. *Can J Neurol Sci* 1994; 21:311-318.
22. Testa D, Savoardo M, Fetoni V, et al. Multiple system atrophy. Clinical and MR observations on 42 cases. *Ital J Neuro Sci* 1993; 14:211-216.
23. Mathias CJ. Autonomic dysfunction. *Brit J Hosp Med* 1987; 38:238-243.
24. Schulz JB, Klockgether T, Petersen D, et al. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. *J Neurol Neurosurg Psychiatry* 1994; 57:1047-1056.
25. Litvan I, Goetz CG, Jankovic J, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. *Arch Neurol* 1997; 54:937-944.
26. Litvan I, Agid Y, Calne D, et al. NINDS-SPSP clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). *Neurology* 1996; 47:1-9.

Second consensus statement on the diagnosis of multiple system atrophy



S. Gilman, MD, FRCP
G.K. Wenning, MD,
PhD
P.A. Low, MD,
FRACP, FRCP(Hon)
D.J. Brooks, MD, DSc,
FRCP, FMedSci
C.J. Mathias, MBBS,
DPhil, DSc, FRCP,
FMedSci
J.Q. Trojanowski, MD,
PhD
N.W. Wood, MB, ChB,
PhD, FRCP
C. Colosimo, MD
A. Dürr, MD, PhD
C.J. Fowler, FRCP
H. Kaufmann, MD
T. Klockgether, MD,
PhD
A. Lees, MD, FRCP
W. Poewe, MD
N. Quinn, MD, FRCP
T. Revesz, MD
D. Robertson, MD
P. Sandroni, MD, PhD
K. Seppi, MD
M. Vidailhet, MD, PhD

ABSTRACT

Background: A consensus conference on multiple system atrophy (MSA) in 1998 established criteria for diagnosis that have been accepted widely. Since then, clinical, laboratory, neuropathologic, and imaging studies have advanced the field, requiring a fresh evaluation of diagnostic criteria. We held a second consensus conference in 2007 and present the results here.

Methods: Experts in the clinical, neuropathologic, and imaging aspects of MSA were invited to participate in a 2-day consensus conference. Participants were divided into five groups, consisting of specialists in the parkinsonian, cerebellar, autonomic, neuropathologic, and imaging aspects of the disorder. Each group independently wrote diagnostic criteria for its area of expertise in advance of the meeting. These criteria were discussed and reconciled during the meeting using consensus methodology.

Results: The new criteria retain the diagnostic categories of MSA with predominant parkinsonism and MSA with predominant cerebellar ataxia to designate the predominant motor features and also retain the designations of definite, probable, and possible MSA. Definite MSA requires neuropathologic demonstration of CNS α -synuclein-positive glial cytoplasmic inclusions with neurodegenerative changes in striatonigral or olivopontocerebellar structures. Probable MSA requires a sporadic, progressive adult-onset disorder including rigorously defined autonomic failure and poorly levodopa-responsive parkinsonism or cerebellar ataxia. Possible MSA requires a sporadic, progressive adult-onset disease including parkinsonism or cerebellar ataxia and at least one feature suggesting autonomic dysfunction plus one other feature that may be a clinical or a neuroimaging abnormality.

Conclusions: These new criteria have simplified the previous criteria, have incorporated current knowledge, and are expected to enhance future assessments of the disease.

Neurology 2008;71:670-676

GLOSSARY

[¹¹C]HED = [¹¹C]hydroxyephedrine; AAN = American Academy of Neurology; AAS = American Autonomic Society; DSM-IV = *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition; DWI = diffusion-weighted imaging; ED = erectile dysfunction; FDG = [¹⁸F]fluorodeoxyglucose; FXTAS = fragile X-associated tremor/ataxia syndrome; MCP = middle cerebellar peduncle; MIBG = [¹²³I]metaiodobenzylguanidine; MR = magnetic resonance; MSA = multiple system atrophy; MSA-C = MSA with predominant cerebellar ataxia; MSA-P = MSA with predominant parkinsonism; OH = orthostatic hypotension; PD = Parkinson disease; SCA = spinocerebellar ataxia; SMC = Safety Monitoring Committee; RV = residual volume; UPDRS = Unified Parkinson's Disease Rating Scale.

Multiple system atrophy (MSA) is an adult-onset, sporadic, progressive neurodegenerative disease characterized by varying severity of parkinsonian features, cerebellar ataxia, autonomic failure, urogenital dysfunction, and corticospinal disorders.¹⁻⁴ The disease frequently begins with bladder dysfunction, and in males erectile dysfunction (ED) usually precedes this complaint.⁵ The presenting motor disorder most commonly consists of parkinsonism with bradykinesia, rigidity, gait instability, and at times tremor, but cerebellar ataxia is the initial motor disorder in a substantial percentage of patients.² The defining neuropathology of MSA consists of degeneration of striatonigral and olivopontocerebellar structures accompanied by profuse

Address correspondence and reprint requests to Dr. Sid Gilman, Department of Neurology, University of Michigan, 300 N. Ingalls St., J1D15, Ann Arbor, MI 48109-5489
sgilman@umich.edu

Author's affiliations are listed at the end of the article.

Supported in part by grants from the NIH (National Institute of Neurological Disorders and Stroke grant 1 R13 NS055459), Novartis Pharmaceuticals, and Chelsea Therapeutics.

Disclosure: Author disclosures are provided at the end of the article.

numbers of distinctive glial cytoplasmic inclusions formed by fibrillized α -synuclein proteins.⁶⁻⁸ Although the etiology is unknown, this disorder, like Parkinson disease (PD) and dementia with Lewy bodies, seems to result from a disturbance of α -synuclein and is designated as an α -synucleinopathy.

A consensus conference on diagnosis held in 1998 defined two categories, MSA with predominant parkinsonism (MSA-P) and MSA with predominant cerebellar ataxia (MSA-C).⁵ Three levels of certainty were established, possible, probable, and definite MSA, with the diagnosis of definite MSA requiring autopsy confirmation. These guidelines emphasized the importance of autonomic by requiring this feature for the diagnosis of probable MSA. Validation studies of the consensus criteria demonstrated high predictive accuracy but suboptimal sensitivity, particularly in the early stages of the disease.^{9,10} For the category of possible MSA, predictive accuracy was relatively lower at the first neurologic visit, but sensitivity was higher at this time point as compared with criteria defining probable MSA.

Widely accepted, the original consensus criteria have served as the gold standard for diagnosis. Nevertheless, the criteria used separate features and criteria for diagnosis that were complex and difficult to keep in mind. Moreover, additional information relevant to diagnostic criteria has accumulated since these criteria were published, including clinical and laboratory studies,⁴ neuropathologic and biochemical findings,^{8,11} and neuroimaging studies.¹²⁻¹⁴ Accordingly, the time had come to initiate a second consensus conference to develop new guidelines for diagnosis. These guidelines are intended for both practicing clinical neurologists and investigators studying the disease.

METHODS Development of this consensus conference began with a grant application to the NIH for support. The grant was funded, additional support was obtained, and the American Academy of Neurology (AAN) agreed to cosponsor the event. A Steering Committee was selected that included investigators with expertise in MSA-P (G.K.W.), MSA-C (S.G.), and autonomic failure (P.A.L.). The Steering Committee selected members for the consensus group based on the members' expertise in the parkinsonian, cerebellar, and autonomic features; in the neu-

ropathologic and biochemical disturbances; and in the structural and functional imaging characteristics of the disease. Selection of members required evidence that they were active investigators and published in the areas relevant to the diagnostic considerations, and included efforts to involve qualified women and minorities in the group. All of those who were contacted initially agreed to serve, and they were divided into five task groups: MSA-P, MSA-C, Autonomic, Neuropathology, and Neuroimaging. A Chair was appointed for each group based on a long track record of leadership in the discipline of the group. The MSA-P group included Gregor K. Wenning (Chair), Carlo Colosimo, Andrew Lees, Werner Poewe, Niall Quinn, and Marie Vidailhet. Members of the MSA-C group were Nicholas W. Wood (Chair), Alexandra Dürr, Thomas Klockgether, and Sid Gilman. The Autonomic group consisted of Christopher J. Mathias (Chair), Clare J. Fowler, Horacio Kaufmann, Phillip A. Low, David Robertson, and Paola Sandroni. The Neuroimaging group included David J. Brooks (Chair) and Klaus Seppi. The Neuropathology group consisted of John Q. Trojanowski (Chair) and Tamas Revesz.

Each task group received from the Steering Committee a request to develop a position paper regarding consensus criteria for diagnosis limited to their area of expertise. The task group chairs initially wrote the position papers, sent them to group members for comments and criticism, and after an iterative process, sent their draft reports to the Steering Committee. The Committee reviewed them and returned them to the task group chairs with comments as needed. Final drafts of the position papers were circulated to the entire membership of the consensus committee in advance of the meeting. A 2-day meeting was held in Boston, Massachusetts, on April 26 and 27, 2007, immediately preceding the AAN meeting. The meeting involved the use of consensus methodology to arrive at the current criteria for diagnosis. Consensus methodology uses the collected judgment of seasoned investigators closely familiar with the disease from years of experience. The consensus process involves the following principles: all members 1) contribute to the discussion, 2) can state each issue in their own words, 3) have the opportunity and time to express their opinion about each issue, and 4) agree to take responsibility for the implementation of a decision. Members who disagree will agree to support the group decision initially on a trial basis, pending further discussion. Achieving consensus requires that all members 1) listen nonjudgmentally to the opinions of other members and 2) check for understanding by summarizing what they think they hear while building on each other's thoughts and exploring minority opinions. The advantages of this methodology are that the quality of a decision is often excellent because it is based on shared information and opinion; and the level of support for each decision is often great because all members participate in making the decision and there is no minority group whose opinions are discounted. The Steering Committee developed the present article with contributions from the entire membership of the consensus group.

RESULTS Diagnostic categories. Similar to the first consensus conference, we determined that the diagnosis of MSA should be divided into three groups. The first, definite MSA, requires the neuropathologic findings of widespread and abundant CNS α -synuclein-positive glial cytoplasmic inclusions (Papp-Lantos inclusions) in association with neurodegenerative changes in striatonigral or olivopontocerebellar

Table 1 Criteria for the diagnosis of probable MSA

A sporadic, progressive, adult (>30 y)-onset disease characterized by

- Autonomic failure involving urinary incontinence (inability to control the release of urine from the bladder, with erectile dysfunction in males) or an orthostatic decrease of blood pressure within 3 min of standing by at least 30 mm Hg systolic or 15 mm Hg diastolic and
- Poorly levodopa-responsive parkinsonism (bradykinesia with rigidity, tremor, or postural instability) or
- A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction)

MSA = multiple system atrophy.

structures.¹⁵ Criteria for probable MSA are listed in table 1 and for possible MSA are listed in tables 2 and 3.³ Patients with predominantly parkinsonian features should continue to be designated MSA-P, and patients with predominantly cerebellar ataxia should be designated MSA-C. We appreciate that the predominant motor feature can change with time; thus, patients who present with cerebellar ataxia can develop increasingly severe parkinsonian features until these latter features dominate the clinical presentation. Hence the designation of MSA-P or MSA-C refers to the predominant feature at the time the patient is evaluated, and the predominant feature can change with time. Also, determining the predominant feature becomes a matter of clinical judgment in subjects with combinations of parkinsonian and cerebellar features. We do not recommend using the term "MSA-mixed" to describe patients with combinations of cerebellar ataxia and parkinsonian features, because this category could be used as a default for any combination of ataxia and parkinsonism, irrespective of the severity of each. Disease onset is defined as the initial presentation of any motor problem, whether parkinsonian or cerebellar, or autonomic features, as defined in the criteria for possible MSA, with the exception of male ED. Although the disease process must start earlier within the CNS, for research purposes, a pragmatic definition of disease onset is required. We excluded ED in men⁵ and reduced genital sensitivity in women¹⁶ because these symptoms have myriad causes in older people. Table 1 provides the criteria for autonomic failure, which is an integral part of MSA, and table 4 gives features supporting and not supporting a diagnosis of MSA for cases with possible MSA.

Autonomic failure. Orthostatic hypotension (OH) may indicate autonomic failure and can be asymptomatic or symptomatic. When symptomatic, it frequently occurs after the onset of ED and urinary symptoms.⁵ Symptoms of OH result from hypoperfusion, and syncope may occur.¹⁷ The clinical diagnosis of probable MSA requires a reduction of systolic blood pressure by at least 30 mm Hg or of diastolic blood pressure by at least 15 mm Hg after 3 minutes of standing from a previous 3-minute interval in the recumbent position. This orthostatic decline is usually accompanied by a compensatory increase in heart rate that is inadequately low for the level of blood pressure decline. We note that this is a more pronounced decrease of blood pressure than recommended previously in the American Autonomic Society (AAS)-AAN consensus statement on the definition of orthostatic hypotension.¹⁸ Blood pressure can be decreased additionally by drugs, fluid depletion, food ingestion, an increased temperature, and physical deconditioning. Other disorders known to cause OH, such as diabetes mellitus with autonomic neuropathy, should be excluded or at least taken into account.

Genitourinary dysfunction. ED is often the earliest symptom of MSA and affects virtually all male patients⁵; apart from one report of decreased genital sensitivity,¹⁶ there is little information about female sexual dysfunction in MSA. Because the prevalence of ED increases with age, the symptom has a low specificity; however, preserved erectile function makes a diagnosis of MSA unlikely. Urinary complaints are common in the aging population, but the recent, unexplained onset of urinary incontinence,

Table 2 Criteria for possible MSA

A sporadic, progressive, adult (>30 y)-onset disease characterized by

- Parkinsonism (bradykinesia with rigidity, tremor, or postural instability) or
- A cerebellar syndrome (gait ataxia with cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction) and
- At least one feature suggesting autonomic dysfunction (otherwise unexplained urinary urgency, frequency or incomplete bladder emptying, erectile dysfunction in males, or significant orthostatic blood pressure decline that does not meet the level required in probable MSA) and
- At least one of the additional features shown in table 3

MSA = multiple system atrophy.

Table 3 Additional features of possible MSA

Possible MSA-P or MSA-C

- Babinski sign with hyperreflexia
- Stridor

Possible MSA-P

- Rapidly progressive parkinsonism
- Poor response to levodopa
- Postural instability within 3 y of motor onset
- Gait ataxia, cerebellar dysarthria, limb ataxia, or cerebellar oculomotor dysfunction
- Dysphagia within 5 y of motor onset
- Atrophy on MRI of putamen, middle cerebellar peduncle, pons, or cerebellum
- Hypometabolism on FDG-PET in putamen, brainstem, or cerebellum

Possible MSA-C

- Parkinsonism (bradykinesia and rigidity)
- Atrophy on MRI of putamen, middle cerebellar peduncle, or pons
- Hypometabolism on FDG-PET in putamen
- Presynaptic nigrostriatal dopaminergic denervation on SPECT or PET

MSA = multiple system atrophy; MSA-P = MSA with predominant parkinsonism; MSA-C = MSA with predominant cerebellar ataxia; FDG = [¹⁸F]fluorodeoxyglucose.

especially in men, and incomplete bladder emptying increase the likelihood of a diagnosis of MSA. Constipation often accompanies the other autonomic symptoms.

Laboratory investigations of autonomic failure. Autonomic failure can be evaluated not only by a history of urinary incontinence and orthostatic blood pressure measurements in the clinic, but also by a comprehensive battery that examines the distribution and severity of cardiovascular, sudomotor, and urinary bladder deficits.¹⁹ Cardiovascular and sudomotor autonomic function tests may help to separate MSA

from other sporadic cerebellar ataxias and from PD.²⁰ Measurement of urine residual volume (RV) by ultrasound can reveal incomplete bladder emptying of >100 mL. RV tends to increase as MSA progresses. Imaging of cardiac innervation with SPECT and [¹²³I]metaiodobenzylguanidine (MIBG) and with PET and [¹⁸F]fluorodopa in many reports have shown preserved sympathetic postganglionic neurons in MSA, in contrast to PD²¹; however, some MIBG studies have shown denervation in MSA,²² and a recent investigation with PET and [¹¹C]hydroxyephedrine ([¹¹C]HED) revealed severe cardiac denervation in MSA.²³

Parkinsonism. Most MSA patients develop parkinsonism (bradykinesia with rigidity, tremor, or postural instability) at some stage. The tremor is usually irregular and postural/action, often incorporating myoclonus, but a classic pill-rolling rest tremor is uncommon. The parkinsonism can be asymmetric. Postural instability, as defined by item 30 of the Unified Parkinson's Disease Rating Scale (UPDRS) part III (motor examination),²⁴ occurs earlier and progresses more rapidly than in PD. Moreover, the UPDRS part III score typically worsens by less than 10% per annum in PD but by more than 20% in MSA.²⁵

Levodopa responsiveness. Parkinsonism usually responds poorly to chronic levodopa therapy; however, up to 30% of patients show a clinically significant, but usually waning, response.²⁶ Responsiveness should be tested with escalating doses of levodopa with a peripheral decarboxylase inhibitor over 3 months up to at least 1 g/d (if necessary and tolerated). A positive response is defined as clinically significant motor improvement. This should be demonstrated by objective evidence such as an improvement of 30% or more on part III of the UPDRS or on part II of the Unified Multiple System Atrophy Rating Scale.²⁷

Sleep disorders. REM sleep behavior disorder and obstructive sleep apnea occur frequently in MSA, but also affect PD patients and are not diagnostically definitive.²⁸

Laboratory investigations. Structural and functional imaging can assist diagnosis. MRI demonstration of putaminal, pontine, and middle cerebellar peduncle (MCP) atrophy is helpful in both MSA-P and MSA-C.²⁹ T2-signal changes on 1.5-tesla MRI in the basal ganglia and brainstem can be helpful, including posterior putaminal hypointensity, hyperintense lateral putaminal rim, hot cross bun sign, and MCP hyperintensities.

Functional imaging demonstration of striatal or brainstem hypometabolism by PET with [¹⁸F]fluorodeoxyglucose can help in the diagnosis of MSA.¹⁷ In the absence of clinically evident ataxia in a patient

Table 4 Features supporting (red flags) and not supporting a diagnosis of MSA

Supporting features	Nonsupporting features
• Orofacial dystonia	• Classic pill-rolling rest tremor
• Disproportionate antecollis	• Clinically significant neuropathy
• Camptocormia (severe anterior flexion of the spine) and/or Pisa syndrome (severe lateral flexion of the spine)	• Hallucinations not induced by drugs
• Contractures of hands or feet	• Onset after age 75 y
• Inspiratory sighs	• Family history of ataxia or parkinsonism
• Severe dysphonia	• Dementia (on DSM-IV)
• Severe dysarthria	• White matter lesions suggesting multiple sclerosis
• New or increased snoring	
• Cold hands and feet	
• Pathologic laughter or crying	
• Jerky, myoclonic postural/action tremor	

MSA = multiple system atrophy; DSM-IV = *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition.

with parkinsonian features, demonstration of cerebellar hypometabolism can point to the diagnosis of MSA-P rather than PD. Conversely, in the absence of parkinsonian features in a patient with cerebellar ataxia, evidence of nigrostriatal dopaminergic denervation from functional imaging (SPECT and PET) may point to the diagnosis of MSA-C.³⁰ As noted above, cardiac sympathetic postganglionic imaging with SPECT shows denervation in PD³¹ and uncommonly in MSA,²² but PET with [¹¹C]HED may reveal extensive denervation in MSA.²³

Other imaging techniques, such as brain parenchymal sonography, magnetic resonance (MR) spectroscopy, MR diffusion-weighted imaging (DWI), MR diffusion tensor imaging, MR magnetization transfer imaging, and MR voxel-based morphometry remain investigational; however, MR DWI has been shown to discriminate MSA-P, even in the early disease stages, from PD and from healthy controls on the basis of increased putaminal and MCP diffusivity measures.³¹

The CSF neurofilament light chain and tau tests have been reported to differentiate MSA from PD but remain in an exploratory phase of development.³²

Cerebellar ataxia. Ataxia of gait, the most common cerebellar feature of MSA-C, is often accompanied by ataxia of speech (cerebellar dysarthria) and cerebellar oculomotor dysfunction. Limb ataxia may be seen but is generally less prominent than gait or speech disturbances. Although gaze-evoked nystagmus occurs in the majority of later-stage MSA-C patients, earlier oculomotor abnormalities may not involve nystagmus, but include square wave jerks, jerky pursuit, and dysmetric saccades. Limitations of supranuclear gaze and severe slowing of saccadic velocities are not features of MSA.

Differential diagnosis of adult-onset cerebellar ataxia. The criteria for probable MSA-C shown in table 1 have high predictive value.^{9,10} MSA-C generally presents clinically as a midline cerebellar disorder that progresses more rapidly than other late-onset sporadic ataxias; typically a patient becomes wheelchair dependent by 5 years after onset.³³ The features detailed in tables 2 and 3 for possible MSA help to provide strong indicators of the diagnosis of MSA-C, and table 4 indicates features supporting and not supporting a diagnosis of MSA. Clinicians evaluating patients with progressive ataxia should include a large differential diagnostic list, because many diseases can produce an adult-onset progressive ataxia. The dominantly inherited spinocerebellar ataxias (SCAs) can result in an apparently sporadic disorder, because even with a negative family history, there is a 15% to 20% chance of a mutation in one of the polyglutamine SCAs, notably SCAs 1, 2, 3, 6, and 7. Fragile

X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder with core features of action tremor and ataxia of gait.³⁴ Frequently this disorder includes parkinsonism, abnormalities of executive function, dementia, neuropathy, and autonomic failure. FXTAS results from a premutation (moderate expansions of 55–200 repeats) of a CGG trinucleotide in the fragile X mental retardation 1 gene, the gene that causes fragile X syndrome when the full mutation develops (over 200 CGG repeats). A search for the fragile X mutation in a large series of possible, probable, and pathologically confirmed cases suggests the frequency is less than 1%.³⁵ FXTAS shows characteristic MRI features, hyperintensity in the middle cerebellar peduncles and supratentorial white matter, that may overlap with those of MSA. A diagnosis of paraneoplastic disease should be considered in patients with an aggressive clinical course with or without general systemic malaise, and a search for appropriate antibodies and for the putative primary should be undertaken. After these diseases have been excluded, and anatomic imaging shows cerebellar and brainstem atrophy, patients usually receive the diagnosis of sporadic adult-onset ataxia, which is also known as idiopathic late-onset cerebellar ataxia or sporadic olivopontocerebellar atrophy.³⁶ The cause of this disorder is unknown, and many patients who develop this disorder do not progress to MSA.

Findings that cast doubt on the diagnosis of MSA-C. The presence of a family history of a similar disorder makes the diagnosis of MSA-C unlikely; one of the SCAs should be considered. Nevertheless, recent studies of several multiplex families suggest familial MSA may be due to autosomal recessive inheritance,³⁷ and autopsy-confirmed MSA has been reported in association with an abnormal expansion of one allele of the SCA type 3 gene.³⁸ Dementia also makes the diagnosis of MSA-C unlikely. MRI studies showing supratentorial white matter lesions other than those commonly seen in this age group make the diagnosis doubtful and raise the possibility of MS.

Differences between the first and second consensus criteria. Although the current criteria have the same structure as the earlier criteria, there are differences in each category. In the previous criteria for definite MSA, α -synuclein-positive glial cytoplasmic inclusions were not required. The previous criteria for probable MSA used separate “features” and “criteria,” which have been abandoned in the current criteria. Similarly, the separate “features” and “criteria” in possible MSA have been deleted and, in addition to parkinsonism or a cerebellar syndrome, now there must be one feature involving autonomic dysfunction.

tion plus one other finding, and the latter is detected either with clinical examination or with imaging.

DISCUSSION On clinical presentation, MSA appears with a combination of autonomic failure with parkinsonism or cerebellar ataxia or both, and the previous criteria and the present criteria recognize this fundamental feature of the disease. The current criteria also retain the distinctions between levels of diagnostic certainty, using the term *definite MSA* for subjects with autopsy demonstration of typical histologic features,¹⁵ *probable MSA* for patients with autonomic failure plus parkinsonism or cerebellar ataxia, and *possible MSA* for people with clinical findings that do not as yet clearly represent this disease.

The principal differences between the current criteria and the previous criteria concern clinical domains and requirements for the diagnosis of possible MSA. In the previous criteria, we used "features" to describe clinical findings and "criteria" to indicate the features that could be used for diagnosis. This distinction proved to be confusing and difficult to retain; hence it has been discarded. The current criteria include straightforward descriptions of the clinical findings required for the diagnoses of probable and possible MSA. The diagnosis of probable MSA is now considerably simplified, as shown in table 1. The diagnosis of possible MSA has been changed to require at least one feature suggesting autonomic dysfunction in addition to parkinsonism or a cerebellar syndrome. At least one additional feature will be required for this diagnosis and can include findings on history, clinical examination, and results from either structural or functional imaging. This change, particularly the requirement of a feature suggesting autonomic dysfunction, hopefully will decrease the false positives that characterize clinical diagnosis in the early stages of the disorder.

The new criteria were created using consensus methodology, as were the first consensus criteria. This methodology presents the advantage of using the collected experience of active investigators, but the disadvantage that the criteria do not result from an evidence-based approach. We anticipate that validation studies will be performed in the future and that these studies will show the high predictive accuracy of the first set of criteria and hopefully better sensitivity in the early stages of the disease than the previous criteria.^{9,10}

We anticipate that the new criteria will be less cumbersome to apply in patients with possible MSA than the first set of criteria. The principal differences between the first and second set of consensus criteria are in the group with possible MSA, and in this group it is possible now to use both clinical and im-

aging results to buttress the diagnosis in subjects with parkinsonian features or cerebellar dysfunction plus autonomic symptoms that do not meet the level needed for the diagnosis of probable MSA. In the latter group, we use criteria for autonomic failure that are more rigorous than those used by the AAS and AAN.¹⁸ This is to ensure a high level of accuracy in the diagnosis of MSA, because the disease is a grave one and carries the prognosis of a markedly shortened life span.

AFFILIATIONS

From the Departments of Neurology, University of Michigan (S.G.), Ann Arbor, MI; Medical University of Innsbruck (G.K.W., W.P., K.S.), Austria; Mayo Clinic Rochester (P.A.L., P.S.), Minnesota; and University Hospital Bonn (T.K.), Germany; Hammersmith Hospital and Department of Clinical Neuroscience (D.B.), Imperial College London, UK; Neurovascular Medicine (Piekering) Unit Faculty of Medicine (C.J.M.), Imperial College London, UK; Department of Pathology and Laboratory Medicine (J.Q.T.), University of Pennsylvania, Philadelphia, PA; National Hospital Queen Square (N.W.W., C.F., A.L., N.Q., T.R.), London, UK; Department of Neurological Sciences (C.C.), University of Rome La Sapienza, Italy; INSERM U289 Hôpital de la Salpêtrière (A.D.), Paris, France; New York University School of Medicine (H.K.), New York, NY; Vanderbilt University Clinical Research Center (D.R.), Nashville, TN; and Federation of Neurology and INSERM U679 (M.V.), Pierre Marie Curie Paris-6 University, France.

DISCLOSURE

S.G. serves as Chair of the Safety Monitoring Committee (SMC) for the Elan and Wyeth trials of immunotherapy for Alzheimer disease and of the SMC for the Elan and Transition trials of scyllo-inositol for Alzheimer disease. He has served as a consultant for Wyeth, ReNeuron, Adamas, and Kyowa and has grant support from Cortex Pharmaceuticals. He is a consultant for PPD Development, Longitude Capital, and the Gerson Lehrman Group and a member of the Board of Directors of Balboa Bioscience. C.C. has received grant support and other honoraria from Allergan, Boehringer-Ingelheim, Eli-Lilly, GlaxoSmithKline, and Ipsen. W.P. has served as a consultant for GSK, Novartis, Teva, Boehringer Ingelheim, Schwarz Pharma/UCB, AstraZeneca, and General Electric. N.Q. has served as a consultant for Medtronic, Schwarz-Pharma, UCB, Boehringer & Ingelheim, GlaxoSmithKline, Daiippon Sumitomo, Solvay, Teva, and Novartis. The remaining authors have no disclosures.

Received January 4, 2008. Accepted in final form May 23, 2008.

REFERENCES

1. Quinn N. Multiple system atrophy—the nature of the beast. *J Neurol Neurosurg Psychiatry* 1989;(suppl):78–89.
2. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. *Mov Disord* 1997;12:133–147.
3. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. *J Neurol Sci* 1999;163:94–98.
4. Geser F, Wenning GK, Seppi K, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). *Mov Disord* 2006;21:179–186.
5. Kirchof K, Apostolidis AN, Mathias CJ, Fowler CJ. Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study. *Int J Impot Res* 2003;15:293–298.
6. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy

- (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). *J Neurol Sci* 1989;94:79–100.
7. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lansbury PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. *Neurosci Lett* 1998;251:205–208.
 8. Ozawa T, Healy DG, Abou-Sleiman PM, et al. The alpha-synuclein gene in multiple system atrophy. *J Neurol Neurosurg Psychiatry* 2006;77:464–467.
 9. Osaki Y, Wenning GK, Daniel SE, et al. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? *Neurology* 2002;59:1486–1491.
 10. Colosimo C, Vanacore N, Bonifati V, et al. Clinical diagnosis of multiple system atrophy: level of agreement between Quinn's criteria and the consensus conference guidelines. *Acta Neurol Scand* 2001;103:261–264.
 11. Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. *Brain* 2004;127:2657–2671.
 12. Seppi K, Schocke MF, Mair KJ, et al. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. *Neuroimage* 2006;31:240–245.
 13. Seppi K, Schocke MF, Donnemiller E, et al. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. *Mov Disord* 2004;19:1438–1445.
 14. Gilman S. Functional imaging with positron emission tomography in multiple system atrophy. *J Neural Transm* 2005;112:1647–1655.
 15. Trojanowski JQ, Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. *Neuropathol Appl Neurobiol* 2007;33:615–620.
 16. Oerterl WH, Wachter T, Quinn NP, Ullm G, Brandstadter D. Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type. *Mov Disord* 2003;18:430–432.
 17. Allcock LM, Ulliyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2004;75:1470–1471.
 18. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. *Neurology* 1996;46:1470.
 19. Suarez GA, Opfer-Gehrking TL, Offord KP, Atkinson EJ, O'Brien PC, Low PA. The Autonomic Symptom Profile: a new instrument to assess autonomic symptoms. *Neurology* 1999;52:523–528.
 20. Sandroni P, Ahlskog JE, Fealey RD, Low PA. Autonomic involvement in extrapyramidal and cerebellar disorders. *Clin Auton Res* 1991;1:147–155.
 21. Courbon F, Brefel-Courbon C, Thalamas C, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. *Mov Disord* 2003;18:890–897.
 22. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2005;76:249–251.
 23. Raffel DM, Koeppe RA, Little R, et al. PET measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes. *J Nucl Med* 2006;47:1769–1777.
 24. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson Disease Rating Scale. Floral Park, NJ: Macmillan, 1987.
 25. Seppi K, Yekhelef F, Diem A, et al. Progression of parkinsonism in multiple system atrophy. *J Neurol* 2005;252:91–96.
 26. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. *J Neurol Neurosurg Psychiatry* 1992;55:1009–1013.
 27. Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). *Mov Disord* 2004;19:1391–1402.
 28. Iranzo A, Santamaria J, Rye DB, et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. *Neurology* 2005;65:247–252.
 29. Seppi K, Schocke MF, Wenning GK, Poewe W. How to diagnose MSA early: the role of magnetic resonance imaging. *J Neural Transm* 2005;112:1625–1634.
 30. Gilman S, Koeppe RA, Junck L, et al. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. *Ann Neurol* 1999;45:769–777.
 31. Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. *Brain* 2006;129:2679–2687.
 32. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. *Neurobiol Aging* 2007;28:742–747.
 33. Klockgether T, Ludtke R, Kramer B, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. *Brain* 1998;121(pt 4):589–600.
 34. Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines. *Mov Disord* 2007;22:2018–2030.
 35. Kamm C, Healy DG, Quinn NP, et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. *Brain* 2005;128:1855–1860.
 36. Abele M, Minnerop M, Urbach H, Specht K, Klockgether T. Sporadic adult onset ataxia of unknown etiology: a clinical, electrophysiological and imaging study. *J Neurol* 2007;254:1384–1389.
 37. Hara K, Momose Y, Tokiguchi S, et al. Multiplex families with multiple system atrophy. *Arch Neurol* 2007;64:545–551.
 38. Nirenberg MJ, Libien J, Vonsattel JP, Fahn S. Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation. *Mov Disord* 2007;22:251–254.

Multiplex Families With Multiple System Atrophy

Kenju Hara, MD, PhD; Yoshio Momose, MD, PhD; Susumu Tokiguchi, MD, PhD; Mitsuteru Shimohata, MD, PhD; Kenshi Terajima, MD, PhD; Osamu Onodera, MD, PhD; Akiyoshi Kakita, MD, PhD; Mitsunori Yamada, MD, PhD; Hitoshi Takahashi, MD, PhD; Motoyuki Hirasawa, MD, PhD; Yoshikuni Mizuno, MD, PhD; Katsuhisa Ogata, MD, PhD; Jun Goto, MD, PhD; Ichiro Kanazawa, MD, PhD; Masatoyo Nishizawa, MD, PhD; Shoji Tsuji, MD, PhD

Background: Multiple system atrophy (MSA) has been considered a sporadic disease, without patterns of inheritance.

Objective: To describe the clinical features of 4 multiplex families with MSA, including clinical genetic aspects.

Design: Clinical and genetic study.

Setting: Four departments of neurology in Japan.

Patients: Eight patients in 4 families with parkinsonism, cerebellar ataxia, and autonomic failure with age at onset ranging from 58 to 72 years. Two siblings in each family were affected with these conditions.

Main Outcome Measures: Clinical evaluation was performed according to criteria by Gilman et al. Trinucleotide repeat expansion in the responsible genes for the spinocerebellar ataxia (SCA) series and for dentatorubral-pallidolusian atrophy (DRPLA) was evaluated by polymerase chain reaction. Direct sequence analysis of coding regions in the α -synuclein gene was performed.

Results: Consanguineous marriage was observed in 1 of 4 families. Among 8 patients, 1 had definite MSA, 5 had probable MSA, and 2 had possible MSA. The most frequent phenotype was MSA with predominant parkinsonism, observed in 5 patients. Six patients showed pontine atrophy with cross sign or slitlike signal change at the posterolateral putaminal margin or both on brain magnetic resonance imaging. Possibilities of hereditary ataxias, including SCA1 (ataxin 1, *ATXN1*), SCA2 (*ATXN2*), Machado-Joseph disease/SCA3 (*ATXN1*), SCA6 (*ATXN1*), SCA7 (*ATXN7*), SCA12 (protein phosphatase 2, regulatory subunit B, β isoform; *PP2R2B*), SCA17 (TATA box binding protein, *TBP*) and DRPLA (atrophin 1; *ATN1*), were excluded, and no mutations in the α -synuclein gene were found.

Conclusions: Findings in these multiplex families suggest the presence of familial MSA with autosomal recessive inheritance and a genetic predisposition to MSA. Molecular genetic approaches focusing on familial MSA are expected to provide clues to the pathogenesis of MSA.

Arch Neurol. 2007;64:545-551

MULTIPLE SYSTEM ATROPHY (MSA) is a sporadic neurodegenerative disorder characterized by various combinations of parkinsonism, cerebellar ataxia, and autonomic failure.¹ The discovery of glial cytoplasmic inclusions (GCIs) established MSA as a distinct neurodegenerative disorder, and α -synuclein was found to be a major component of GCIs.²⁻⁴ Furthermore, α -synuclein in GCIs has been found to be abnormally phosphorylated at Ser129, and phosphorylated α -synuclein has been demonstrated to promote fibril formation *in vitro*.⁵ However, the etiology of MSA remains to be elucidated. Recently, familial cases of MSA with probable autosomal dominant inheritance were reported in Germany and Japan.^{6,7} Herein, we report findings in 4 multiplex families with MSA that

suggest an autosomal recessive model of inheritance.

METHODS

CLINICAL AND PATHOLOGICAL ANALYSIS

We identified 4 Japanese families, families A through D, in which multiple siblings were affected with MSA (**Figure 1**). The diagnosis of MSA was made on the basis of the consensus criteria for MSA by Gilman et al.¹ Brain magnetic resonance (MR) imaging or computed tomography was performed in 7 patients; in the eighth patient (II-4 in family A), an autopsy was performed. Selected histopathological sections of 4- μ m thickness were stained with hematoxylin-eosin, Klüver-Barrera Luxol fast blue, or Gallyas-Braak silver. Immunohistochemical analysis was conducted using an anti- α -synuclein-precursor of the non-A β compo-

Author Affiliations are listed at the end of this article.




Figure 1. Four multiplex families with multiple system atrophy. The affected siblings in family A were born from a consanguineous marriage. In family A, both affected patients (II-4 and II-8) had retinitis pigmentosa (denoted by an asterisk) but not the other siblings. Squares represent men; circles, women; affected individuals, solid symbols; unaffected individuals, open symbols.

ment of Alzheimer disease amyloid (NACP) antibody as previously described.⁸

MOLECULAR GENETIC ANALYSIS

Genomic DNA was extracted from peripheral blood leukocytes after obtaining informed consent. Expansions of CAG repeats of the genes for dominant spinocerebellar ataxias (SCAs), including SCA1 (ataxin 1; *ATXN1* [for gene nomenclature see <http://www.gene.ucl.ac.uk/nomenclature/>]),¹⁰ SCA2 (*ATXN2*),¹¹⁻¹³ Machado-Joseph/SCA3 (*ATXN1*),¹⁴ SCA6 (*ATXN1*),¹⁵ SCA7 (*ATXN7*),¹⁶ SCA12 (protein phosphatase 2, regulatory subunit B, β isoform, *PPP2R2B*),¹⁷ SCA17 (TATA box binding protein, *TBP*),^{18,19} and dentatorubral-pallidolusian atrophy (DRPLA [atrophin 1, *ATN1*]),^{20,21} were analyzed using an automated DNA sequencer (ABI 377; Applied Biosystems, Foster City, Calif) in the affected patients. Direct sequence analysis of 6 coding exons of the α -synuclein (*SNCA*) gene was performed using the ABI 3100 DNA sequencer in all patients.

RESULTS

Two siblings were affected in each family. The parents of siblings in each family had no clinical signs of extrapyramidal or cerebellar disorders. Consanguineous marriage was present in family A, in which the parents were first-degree cousins. Among 8 patients, 1 (II-4 in family A) had definite MSA, 5 (II-8 in family A, II-2 and II-9 in family B, II-5 in family C, and II-7 in family D) had probable MSA, and 2 (II-4 in family C and II-3 in family D) had possible MSA. The most frequent phenotype was MSA with predominant parkinsonism (MSA-P), observed in 5 patients. One patient showed an MSA of the cerebellar type (MSA-C) phenotype, and 2 patients showed an MSA-P+C phenotype. The clinical phenotypes were concordant between the affected siblings in the 3 families (families A, B, and C). The mean age at onset was 65.9 years (age range, 58-72 years). Six patients showed pontine atrophy with cross sign or slitlike signal change at the pos-

terolateral putaminal margin or both on brain MR imaging. Clinical features of 4 multiplex families with MSA are summarized in the **Table**.

Testing for the trinucleotide repeat expansions in the responsible genes for SCA1 (*ATXN1*), SCA2 (*ATXN2*), Machado-Joseph disease/SCA3 (*ATXN1*), SCA6 (*ATXN1*), SCA7 (*ATXN7*), SCA12 (*PPP2R2B*), SCA17 (*TBP*), and DRPLA (*ATN1*) gave normal results. No mutations in the *SNCA* gene were found in the family members.

REPORT OF CASES

FAMILY A

Patient II-4

Patient II-4 was diagnosed as having retinitis pigmentosa at age 33 years by an ophthalmologist. She noticed resting tremor in her left hand at age 68 years, followed by the development of bradykinesia and gait disturbance at age 69 years. Neurological examination at age 71 years revealed bradykinesia, a masklike face, urinary frequency, severe rigidity in the 4 limbs, and limb ataxia predominant on the left side. Parkinsonism was not improved by levodopa treatment. She did not show dementia, muscular atrophy, sensory disturbance, or limitation of ocular movement. Brain computed tomography showed distinct cerebellar atrophy. Brain MR imaging was not performed. She had recurrent pneumonia and died at age 73 years. On postmortem examination, the brain weighed 1030 g before fixation. On gross examination, the cerebellum and pontine base were moderately atrophic. The inferior olivary nuclei were slightly atrophic. Moderate depigmentation in the substantia nigra and locus coeruleus was observed. Microscopically, moderate to severe loss of neurons with gliosis was observed in the pontine nuclei. The transverse bundles in the pontine base

Table. Clinical Findings Among 4 Multiplex Families With Multiple System Atrophy (MSA)

Finding	Family and Affected Individuals							
	A		B		C		D	
	II-4	II-8	II-2	II-9	II-4	II-5	II-3	II-7
Sex	Female	Male	Male	Male	Female	Male	Female	Male
Age at onset, y	68	62	72	63	68	67	69	58
Age at examination, y	71	66	73	66	72	68	72	63
Initial symptoms	Tremor	Ataxia	Tremor	Tremor	Tremor	Ataxia	Akinesia	Impotence
Parkinsonism	*	*	*	*	†	†	*	...
Cerebellar sign	‡	‡	...	‡	‡	†	...	‡
Muscle stretch reflexes								
Upper limb	Enhanced	Normal	Normal	Normal	Normal	Normal	Enhanced	Enhanced
Lower limb	Enhanced	Normal	Normal	Normal	Normal	Normal	Enhanced	Enhanced
Babinski sign	‡	‡
Urinary dysfunction	‡	‡	‡	‡	‡	‡
Orthostatic hypotension	‡	‡	‡	‡
Response to levodopa	‡	‡	‡
Brain magnetic resonance imaging	Poor	Poor	Poor	Poor	Poor	Poor	Poor	Poor
Cerebellar atrophy	NE	‡	...	†	...	‡	‡	‡
Pontine atrophy	NE	‡	...	‡	...	*	‡	*
Cross sign	NE	‡	...	‡	...	‡	...	‡
Slitlike signal change at the posterolateral putaminal margin	NE	‡	‡	‡	‡	‡
Criteria by Gilman et al ¹	Definite	Probable	Probable	Probable	Possible	Probable	Possible	Probable
Phenotypes	MSA-P	MSA-P	MSA-P	MSA-P	MSA-P+C	MSA-P+C	MSA-P	MSA-C
Complication	RP	RP	Rheumatoid arthritis

Abbreviations: MSA-C, MSA of the cerebellar type; MSA-P, MSA with predominant parkinsonism; NE, not examined; RP, retinitis pigmentosa; ellipsis, not applicable.

*Severe finding.
†Moderate finding.
‡Finding present.

showed severe loss of myelinated nerve fibers. The loss of Purkinje cells was mild to moderate, and the cerebellar white matter was severely degenerated. In the cerebellar dentate nucleus, neuronal shrinkage associated with gliosis was observed. Moderate neuronal loss associated with gliosis was observed in the substantia nigra and locus coeruleus. In the putamen, a small amount of GCIs was observed, but no obvious neuronal loss was observed. Mild neuronal loss was also detectable in the red nucleus and dorsal vagal and vestibular nuclei. In the thalamic medial nuclei, gliosis without distinct neuronal loss was observed. Numerous argyrophilic GCIs and an abnormal accumulation of α -synuclein-NACP in glial cells were observed in the substantia nigra, pontine base, inferior olive, and cerebellar white matter (Figure 2). In the retina, severe loss of rods and cones and patchy disappearance of pigmentary epithelial cells were observed.

Patient II-8

Patient II-8 developed night blindness at age 48 years and was diagnosed as having retinitis pigmentosa at age 51 years. He had mild resting tremor in both hands, bradykinesia, and rigidity at age 62 years, which were symmetrical and refractory to a combined therapy of 200 mg of levodopa-dopadecarboxylase inhibitor. He had difficulty in urination at age 63 years, orthostatic hypotension at age 64 years, and truncal ataxia at age




Figure 2. Histopathologic features of the pons from patient II-4 in family A. A, Argyrophilic glial cytoplasmic inclusions (arrows) (Gallyas-Braak stain). B, Abnormal accumulation of α -synuclein-precursor of the non-A β component of Alzheimer disease amyloid (NACP) in glial cells (arrows).

65 years. He became bedridden at age 66 years because of the progression of his symptoms. On laboratory investigation, his protein level, cell counts, glucose concentration, IgG index, and 5-hydroxyindoleacetic acid level in cerebrospinal fluid were within normal ranges. His homovanillic acid level was decreased to 19.9 ng/mL (reference range, 28-77 ng/mL). Thyroid hormone levels, serum and urinary copper levels, serum ceruloplasmin level, lysosomal enzyme activities in leukocytes, and vitamin B₁, B₁₂, and E levels were normal. Nerve conduction studies revealed no abnormalities. Brain MR imaging showed mild atrophy of the




Figure 3. Representative brain magnetic resonance images of patients in the 4 families. A, T1-weighted image of patient II-8 in family A showing slitlike signal change at the posterolateral putaminal margin (arrows). B, T2-weighted image of patient II-2 in family B showing slitlike signal change at the posterolateral putaminal margin (arrows). C, T2-weighted image of patient II-9 in family B showing atrophy of the cerebellar vermis and pons with cross sign (arrow). D, Proton density-weighted image of patient II-5 in family C showing cross sign in the pons (arrow). E, Proton density-weighted image of patient II-7 in family D showing cross sign in the pons (arrow).

pons and cerebral cortex on T1-weighted imaging. Atrophy of the pontine base accompanied by cross sign²² on T2-weighted and proton density-weighted imaging was observed. Slitlike signal changes with hyperintensity on T1-weighted imaging and hypointensity on T2-weighted imaging²³ were observed in the posterolateral putaminal margin (**Figure 3A**). Single-photon emission computed tomography images showed mild hypoperfusion in the pons, basal ganglia, and right frontal and left parietal lobes.

Both affected siblings in family A had retinitis pigmentosa. The other siblings were unaffected.

FAMILY B

Patient II-2

Patient II-2 began to have resting tremor in the right hand at age 72 years, followed by rigidity in the 4 extremities, parkinsonian gait, urinary incontinence, and orthostatic hypotension within a year. These symptoms responded poorly to a combined therapy of 900 mg of levodopa-dopadecarboxylase inhibitor. He required support in walking at age 76 years. Brain MR imaging revealed slitlike signal change at the posterolateral putaminal mar-

gin on T2-weighted imaging and pontine atrophy on T1-weighted imaging (**Figure 3B**).

Patient II-9

The brother of patient II-2, patient II-9, developed resting tremor in the right hand at age 63 years and in the right leg at age 65 years. Neurological examination at age 66 years revealed severe rigidity in the 4 extremities, bradykinesia, mild limb ataxia, urinary incontinence, and orthostatic hypotension. The symptoms responded poorly to a combined therapy of 900 mg of levodopa-dopadecarboxylase inhibitor. Brain MR imaging showed slitlike signal change at the posterolateral putaminal margin, atrophy of the cerebellar vermis, and cross sign in the pons on T2-weighted imaging (**Figure 3C**).

FAMILY C

Patient II-4

Patient II-4 had cerebellar ataxia at age 68 years, followed by the development of resting tremor predominantly on the left side, neck rigidity, parkinsonian gait, and urinary frequency. These symptoms were progres-

sive and responded poorly to a combined therapy of 300 mg of levodopa–dopadecarboxylase inhibitor. She eventually required a wheelchair at age 73 years. Brain MR imaging performed at age 72 years showed no abnormalities.

Patient II-5

The brother of patient II-4, patient II-5, had resting tremor in the left hand, dysarthria, and urinary frequency at age 67 years. These symptoms progressed slowly. He further developed rigidity predominantly on the left side and truncal ataxia. He became wheelchair bound at age 70 years. Brain MR imaging showed severe cerebellar atrophy and pontine atrophy accompanied by cross sign (Figure 3D).

FAMILY D

Patient II-7

Patient II-7 had impotence and constipation at age 58 years and nocturnal urinary frequency at age 60 years. He had cerebellar ataxia at age 62 years and orthostatic hypotension at age 63 years. On physical examination at age 63 years, he showed prominent autonomic dysfunctions, including orthostatic hypotension, urinary frequency, constipation, and impotence. Moderate cerebellar ataxia, pyramidal signs such as Babinski sign with hyperreflexia, and extrapyramidal signs such as rigidity in the neck and upper limbs were also observed. Brain MR imaging showed severe atrophy of the cerebellum and pontine base accompanied by cross sign in the pons on proton density–weighted imaging (Figure 3E) and slitlike signal change at the posterolateral putaminal margin on T2-weighted imaging.

Patient II-3

The sister of patient II-7, patient II-3, had bradykinesia at age 69 years. Neurological examination at age 72 years revealed severe parkinsonism with poor response to levodopa therapy, hyperreflexia of the 4 limbs, and urinary incontinence.

Brain MR imaging showed severe atrophy of the cerebellum and the pons and slitlike signal change at the posterolateral putaminal margin on T2-weighted imaging. The clinical phenotypes were not concordant between the affected siblings in this family.

COMMENT

The 8 patients in 4 families were considered affected with MSA for the following reasons. First, all the affected members fulfilled the consensus criteria for the diagnosis of MSA according to Gilman et al¹ except for family history of a similar disorder. Because it is important to differentiate MSA from progressive supranuclear palsy and from corticobasal degeneration, the consensus guide-

lines comprise exclusion criteria (including prominent slowing of vertical saccades, vertical supranuclear gaze palsy, and evidence of focal cortical dysfunction [such as aphasia, alien limb syndrome, and parietal dysfunction]) to increase the specificity of the diagnosis of MSA. None of the affected members fulfilled these exclusion criteria. Furthermore, none of the affected members fulfilled the clinical criteria for progressive supranuclear palsy²² or corticobasal degeneration.²³ Second, 6 of 8 patients showed pontine atrophy with cross sign or slitlike signal change at the posterolateral putaminal margin or both on brain MR imaging. These findings have been established as radiological evidence for MSA,^{24,25} although such findings have been described infrequently in other diseases, including SCA2,²⁶ Machado-Joseph disease,²⁷ progressive supranuclear palsy,²⁸ and corticobasal degeneration.²⁸ In the families in the present study, SCA2 and Machado-Joseph disease were excluded by molecular diagnosis. Third, the possibilities of SCA12 and SCA17 mimicking parkinsonism and ataxia were excluded by molecular diagnosis as well.

Although MSA has been considered a sporadic neurodegenerative disease, a genetic predisposition to MSA was first described by Nee et al²⁹ in 1991. They found higher frequencies of neurological diseases and autonomic symptoms among 148 first-degree relatives of 33 patients clinically diagnosed as having MSA compared with control subjects. Wenning et al³⁰ reported a higher frequency of parkinsonism among first-degree or second-degree relatives of 38 autopsy-proven patients with MSA. Furthermore, a patient with pathologically proven MSA whose mother had autopsy-proven Parkinson disease was also described.³¹ Recently, 2 families with probable MSA in Germany and Japan have been described; these 2 families each have 2 affected individuals, suggesting autosomal dominant inheritance.^{6,7} In the families in the present study, consanguineous marriage was observed in family A, and no affected individuals were ascertained in successive generations, suggesting a hypothesis of autosomal recessive inheritance. The segregation ratio of 0.129 (95% confidence interval, 0.011–0.247) was estimated based on data from all 4 families. Although the ratio was slightly lower than 0.25, which is expected for an autosomal recessive inheritance model, the distribution of affected individuals in these families might be consistent with that expected for an autosomal recessive inheritance trait considering an ascertainment bias for multiplex families ($\chi^2 = 1.53, P = .22$).³² We need additional multiplex MSA families to formulate any conclusive interpretation on mode of inheritance among our families. A second hypothesis on the genetic model for these families is that MSA susceptibility genes strongly contribute to the pathogenesis among these families. A third hypothesis is that 2 siblings in each family were affected by chance. Because the standardized prevalence rates of MSA are estimated to be 1.9 to 4.9 cases per 100 000 people,¹³ the possibility of finding 2 patients with MSA in a family of 10 or 12 members by chance is below 0.00006. Therefore, incidental occurrence of MSA in a single family is extremely rare.

We can identify some characteristic features of these families. First, most patients had the MSA-P phenotype.

This is inconsistent with the fact that the MSA-C phenotype is the most prevalent form of MSA in Japan. According to a recent nationwide survey in Japan, 82.5% of patients with MSA have the MSA-C phenotype, while 10.6% have the MSA-P phenotype.³⁴ Second, the clinical phenotypes were concordant between the affected siblings in 3 of 4 families. Third, the mean age at onset (65.9 years) of these family members is later than that among patients with sporadic MSA (age range, 55.4-57.5 years).^{35,36} Fourth, pathological changes were prominent in the substantia nigra, while those in the putamen were very mild in patient II-4 in family A, despite the MSA-P phenotype. Because a high degree of neuronal loss in the putamen has been generally observed in subjects with the MSA-P phenotype,³⁶ this observation is interesting. More pathologically proven cases of familial MSA are required to reveal the pathological features of familial MSA.

Because the SNCA gene is the major component of GCIs and of neuronal cytoplasmic inclusions in MSA,^{2,4} we considered this a candidate gene and conducted mutational analysis of the coding regions but failed to find any mutations in our patients. A previous study demonstrated no significant changes in the expression levels of the SNCA gene messenger RNA in the brains of patients with MSA compared with those of control subjects.³⁷ Taken together, the SNCA gene is unlikely to be the causative gene for MSA. Other genetic or environmental factors associated with SNCA might be operable in the pathogenesis of MSA. To identify genetic factors related to MSA, investigations of additional multiplex families with MSA are necessary.

Accepted for Publication: October 27, 2006.

Author Affiliations: Departments of Neurology (Drs Hara, Shimohata, Terajima, and Nishizawa) and Pathology (Drs Yamada and Takahashi), and Genome Science Branch (Dr Onodera) and Resource Branch for Brain Disease Research (Dr Kakita), Center for Bioresource-Based Researches, Brain Research Institute, Niigata University, Niigata; Division of Neuroscience, Department of Neurology, Graduate School of Medicine, University of Tokyo (Drs Momose, Ogata, Goto, and Tsuji), Department of Neurology, Juntendo University School of Medicine (Drs Hirasawa and Mizuno), and National Center of Neurology and Psychiatry (Dr Kanazawa), Tokyo; and Department of Neurology, Toi Clinic, Shizuoka (Dr Tokiguchi); Japan.

Correspondence: Shoji Tsuji, MD, PhD, Division of Neuroscience, Department of Neurology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan (tsuji@m.u-tokyo.ac.jp).

Author Contributions: *Study concept and design:* Hara, Terajima, and Tsuji. *Acquisition of data:* Hara, Momose, Tokiguchi, Shimohata, Terajima, Onodera, Kakita, Yamada, Takahashi, Hirasawa, Mizuno, Ogata, Goto, Kanazawa, and Tsuji. *Analysis and interpretation of data:* Hara, Takahashi, Goto, Nishizawa, and Tsuji. *Drafting of the manuscript:* Hara, Momose, Tokiguchi, Shimohata, Onodera, Kakita, Takahashi, Hirasawa, Mizuno, Ogata, Goto, Kanazawa, Nishizawa, and Tsuji. *Critical revision of the manuscript for important intellectual content:* Hara,

Terajima, Yamada, and Tsuji. *Statistical analysis:* Hara. *Obtained funding:* Hara, Goto, and Tsuji. *Administrative, technical, and material support:* Hara, Tokiguchi, Shimohata, Terajima, Onodera, Kakita, Takahashi, Hirasawa, Ogata, and Tsuji. *Study supervision:* Hara, Terajima, Mizuno, Kanazawa, Nishizawa, and Tsuji.

Financial Disclosure: None reported.

Funding/Support: This study was supported by a Grant-in-Aid for Scientific Research on Priority Areas (C)-Advanced Brain Science Project and by a Grant-in-Aid for Scientific Research (A) from the Japan Ministry of Education, Culture, Sports, Science and Technology; by a Research for the Future Program grant from the Japan Society for the Promotion of Science; by a grant for Surveys and Research on Specific Diseases from the Japan Ministry of Health, Labor and Welfare; by a grant from the Virtual Research Institute of Aging from Nippon Boehringer Ingelheim; and by a grant from the Naito Foundation.

REFERENCES

1. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. *J Neurol Sci*. 1999;163:94-98.
2. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. α -Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. *Neurosci Lett*. 1998;249:180-182.
3. Arima K, Ueda K, Sunohara N, et al. NACP/ α -synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. *Acta Neuropathol (Berl)*. 1998;96:439-444.
4. Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein MJ. α -Synuclein in neurodegenerative disorders: murderer or accomplice? *Nat Med*. 1998;4:755-757.
5. Fujiwara H, Hasegawa M, Dohmae N, et al. α -Synuclein is phosphorylated in synucleinopathy lesions. *Nat Cell Biol*. 2002;4:160-164.
6. Willner U, Abebe M, Huebsh TS, et al. Probable multiple system atrophy in a German family. *J Neurol Neurosurg Psychiatry*. 2004;75:924-925.
7. Soma H, Yabe I, Takei A, Fujiki N, Yanagihara T, Sasaki H. Heredity in multiple system atrophy. *J Neurol Sci*. 2006;240:107-110.
8. Wakabayashi K, Hayashi S, Kakita A, et al. Accumulation of α -synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. *Acta Neuropathol (Berl)*. 1998;96:445-452.
9. HUGO Gene Nomenclature Committee home page. <http://www.gene.ucl.ac.uk/nomenclature>. Accessed February 14, 2007.
10. Orr HT, Chung MY, Banfi S, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. *Nat Genet*. 1993;4:221-226.
11. Imbert G, Saudou F, Yvert G, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. *Nat Genet*. 1996;14:285-291.
12. Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. *Nat Genet*. 1996;14:269-276.
13. Sanpei K, Takano H, Igarashi S, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique. DIRECT. *Nat Genet*. 1996;14:277-284.
14. Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. *Nat Genet*. 1994;8:221-228.
15. Zuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the $\alpha_1\text{-}\text{voltage}$ -dependent calcium channel. *Nat Genet*. 1997;15:62-69.
16. David G, Abbas N, Stevanin G, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. *Nat Genet*. 1997;17:65-70.
17. Holmes SE, O'Hearn EE, McInnis MG, et al. Expansion of a novel CAG trinucleotide repeat in the 5' region of PPP2R2B is associated with SCA12. *Nat Genet*. 1999;23:391-392.
18. Koide R, Kobayashi S, Shimohata T, et al. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease. *Hum Mol Genet*. 1999;8:2047-2053.

19. Nakamura K, Jeong SY, Uchiyama T, et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by the expanded polyglutamine in TATA-binding protein. *Hum Mol Genet.* 2001;10:1441-1448.
20. Koide R, Ikeuchi T, Onodera O, et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). *Nat Genet.* 1994;6:9-13.
21. Nagafuchi S, Yanagisawa H, Sato K, et al. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. *Nat Genet.* 1994;6:14-18.
22. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. *Neurology.* 1996;47:1-9.
23. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. *Ann Neurol.* 2003;54(suppl 5):S15-S19.
24. Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. *J Neurol Neurosurg Psychiatry.* 1998;65:65-71.
25. O'Brien C, Sung JH, McGeachie RE, Lee MC. Striatonigral degeneration: clinical, MRI, and pathologic correlation. *Neurology.* 1990;40:710-711.
26. Burk K, Skalej M, Dichgans J. Pontine MRI hyperintensities ("the cross sign") are not pathognomonic for multiple system atrophy (MSA) [case report]. *Mov Disord.* 2001;16:535.
27. Murata Y, Yamaguchi S, Kawakami H, et al. Characteristic magnetic resonance imaging findings in Machado-Joseph disease. *Arch Neurol.* 1998;55:33-37.
28. Macia F, Yekhelef F, Ballan G, Delmer O, Tison F. T2-hyperintense lateral rim and hypointense putamen are typical but not exclusive of multiple system atrophy [letter]. *Arch Neurol.* 2001;58:1024-1026.
29. Nee LE, Gomez MR, Dambrosia J, Bale S, Eldridge R, Polinsky RJ. Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. *Clin Auton Res.* 1991;1:9-13.
30. Wenning GK, Wagner S, Daniel S, Quinn NP. Multiple system atrophy: sporadic or familial [letter]? *Lancet.* 1993;342:681.
31. Shimo Y, Takanashi M, Ohta S, et al. A 56-year-old woman with parkinsonism, whose mother had Parkinson's disease. *No To Shinkei.* 2001;53:495-505.
32. Cavalli-Sforza LL, Bodmer WF. *The Genetics of Human Populations.* Mineola, NY: Dover Publications Inc; 1999:851-890.
33. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy [published correction appears in *Lancet Neurol.* 2004;3:137]. *Lancet Neurol.* 2004;3:93-103.
34. Tsuji S. MSA update. *Rinsho Shinkeigaku.* 2005;45:821-823.
35. Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. *Brain.* 2004;127:2657-2671.
36. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 100 cases. *Brain.* 2002;125:1070-1083.
37. Ozawa T, Okuzum K, Ikeuchi T, Wakabayashi K, Takahashi H, Tsuji S. Analysis of the expression level of α -synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. *Acta Neuropathol (Berl).* 2001;102:188-190.

Call for Papers

ARCHIVES Express

ARCHIVES EXPRESS

The ARCHIVES launched a new ARCHIVES Express section in the September 2000 issue. This section will enable the editors to publish highly selected papers within approximately 2 months of acceptance. We will consider only the most significant research, the top 1% of accepted papers, on new important insights into the pathogenesis of disease, brain function, and therapy. We encourage authors to send their most exceptional clinical or basic research, designating in the cover letter a request for expedited ARCHIVES Express review. We look forward to publishing your important new research in this accelerated manner.

Roger N. Rosenberg, MD

ORIGINAL ARTICLE

Mutations in *COQ2* in Familial and Sporadic Multiple-System Atrophy

The Multiple-System Atrophy Research Collaboration

ABSTRACT

BACKGROUND

Multiple-system atrophy is an intractable neurodegenerative disease characterized by autonomic failure in addition to various combinations of parkinsonism, cerebellar ataxia, and pyramidal dysfunction. Although multiple-system atrophy is widely considered to be a nongenetic disorder, we previously identified multiplex families with this disease, which indicates the involvement of genetic components.

METHODS

In combination with linkage analysis, we performed whole-genome sequencing of a sample obtained from a member of a multiplex family in whom multiple-system atrophy had been diagnosed on autopsy. We also performed mutational analysis of samples from members of five other multiplex families and from a Japanese series (363 patients and two sets of controls, one of 520 persons and one of 2383 persons), a European series (223 patients and 315 controls), and a North American series (172 patients and 294 controls). On the basis of these analyses, we used a yeast complementation assay and measured enzyme activity of parahydroxybenzoate-polyprenyl transferase. This enzyme is encoded by the gene *COQ2* and is essential for the biosynthesis of coenzyme Q₁₀. Levels of coenzyme Q₁₀ in lymphoblastoid cells and brain tissue were measured on high-performance liquid chromatography.

RESULTS

We identified a homozygous mutation (M128V-V393A/M128V-V393A) and compound heterozygous mutations (R387X/V393A) in *COQ2* in two multiplex families. Furthermore, we found that a common variant (V393A) and multiple rare variants in *COQ2*, all of which are functionally impaired, are associated with sporadic multiple-system atrophy. The V393A variant was exclusively observed in the Japanese population.

CONCLUSIONS

Functionally impaired variants of *COQ2* were associated with an increased risk of multiple-system atrophy in multiplex families and patients with sporadic disease, providing evidence of a role of impaired *COQ2* activities in the pathogenesis of this disease. (Funded by the Japan Society for the Promotion of Science and others.)

The members of the Multiple-System Atrophy Research Collaboration are listed in the Appendix. Address reprint requests to Dr. Shoji Tsuji, Department of Neurology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan, or at tsuji@m.u-tokyo.ac.jp.

This article was published on June 12, 2013, and updated on July 3, 2014, at NEJM.org.

N Engl J Med 2013;369:233-44.
DOI: 10.1056/NEJMoa1212115

Copyright © 2013 Massachusetts Medical Society.

MULTIPLE-SYSTEM ATROPHY IS A progressive neurodegenerative disease that is clinically characterized by autonomic failure in addition to various combinations of parkinsonism, cerebellar ataxia, and pyramidal dysfunction. The term multiple-system atrophy was introduced in 1969 to encompass the disease entities of olivopontocerebellar ataxia, striatonigral degeneration, and the Shy-Drager syndrome, on the basis of neuropathological findings in these disorders.¹ Multiple-system atrophy is characterized by the development of cytoplasmic aggregates of α -synuclein, primarily in oligodendroglia.²⁻⁷ However, the pathogenic mechanisms underlying this disease remain unknown, making it difficult to develop effective therapies.

The disorder is classified into two subtypes: subtype C, characterized predominantly by cerebellar ataxia, and subtype P, characterized predominantly by parkinsonism.⁸ Among patients with multiple-system atrophy, subtype C has been reported to be more prevalent than subtype P in the Japanese population (65 to 67% vs. 33 to 35%),^{9,10} whereas subtype P has been reported to be more prevalent than subtype C in Europe (63% vs. 34%)¹¹ and North America (60% vs. 13%, with 27% of cases unclassified).¹² Although multiple-system atrophy has been defined as a non-genetic disorder until recently, several multiplex families with the disease have been described, indicating that strong genetic factors confer susceptibility to the disease.¹³⁻¹⁵

METHODS

PATIENTS AND MULTIPLEX FAMILIES

Patients with multiple-system atrophy were enrolled in the study on the basis of research protocols that were approved by the institutional review board at each participating center. Written informed consent was obtained from all participants.

The diagnosis of multiple-system atrophy was made on the basis of the current consensus criteria for the disease.⁸ Four Japanese families (Families 1 through 4, whose members have been described previously¹³) and two additional Japanese families (Family 8 and Family 12) were enrolled in this study (Fig. 1). In Family 1, the parents were first-degree cousins, which is consistent with autosomal recessive inheritance. The clinical features of these families are sum-

marized in Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.

Autopsy findings for Participants II-4¹³ and II-8 in Family 1 and Participant II-6 in Family 8 showed widespread and abundant cytoplasmic aggregates of α -synuclein, primarily in oligodendroglia, in association with neurodegeneration in striatonigral and olivopontocerebellar structures. These findings confirmed the diagnosis of multiple-system atrophy.

PATIENTS WITH SPORADIC DISEASE AND CONTROLS

As with the multiplex families, the diagnosis of sporadic multiple-system atrophy was made on the basis of the current consensus criteria.⁸ A total of 363 patients with multiple-system atrophy and 520 controls were included in the Japanese series, 223 patients and 315 controls in the European series, and 172 patients and 294 controls in the North American series (persons of European or Hispanic descent living in North America) (Text S2 and Table S2 in the Supplementary Appendix). Ancestry was determined by self-report on a multiple-choice questionnaire. We also enrolled an independent series of 2383 Japanese controls.

ASSOCIATION WITH OTHER NEURODEGENERATIVE DISEASES

To determine the specificity of the association between variants in candidate genes and multiple-system atrophy, we enrolled 2728 Japanese patients with Alzheimer's disease, 659 with Parkinson's disease, and 634 with amyotrophic lateral sclerosis (ALS). Their demographic characteristics are provided in Text S2 in the Supplementary Appendix.

LINKAGE ANALYSIS AND WHOLE-GENOME SEQUENCING

We performed parametric and nonparametric linkage analyses using Affymetrix SNP 6.0 arrays and software for linkage analysis.^{16,17} The genomic DNA from Participant II-4 in Family 1 was subjected to four runs in an Illumina Genome Analyzer IIx (100-bp-long paired ends). We used BWA software¹⁸ and SAMtools sequence-alignment mapping¹⁹ with the default settings for alignment and variation detection against the human reference genome (National Center for Biotechnology Information build 36 [also known as hg18]).




Figure 1. Pedigrees of Six Multiplex Families with Multiple-System Atrophy.

The affected siblings in Family 1 were born to consanguineous parents (first cousins).^{2,3} In this family, the two patients with multiple-system atrophy (Participants II-4 and II-8) also had retinitis pigmentosa, which was not present in the other siblings. The diagnosis of definite multiple-system atrophy in three patients (Participants II-4 and II-8 in Family 1 and II-6 in Family 8) was confirmed at autopsy. In Family 8, two siblings (Participants II-3 and II-4) of the affected family members had Parkinson's disease (PD). In Family 1, in which homozygous M128V-V393A mutations in *COQ2* were identified, the parents (Participants I-1 and I-2), who were obligate carriers of the mutation, showed no overt signs of parkinsonism, cerebellar ataxia, or autonomic dysfunction, according to family report. In Family 12, in whom compound heterozygous R387X/V393A mutations were identified, Participants I-1 and I-2 (obligate carriers of the mutations) and the heterozygous carrier (Participant II-2) showed no overt signs of parkinsonism, cerebellar ataxia, or autonomic dysfunction on examination by a neurologist. Squares represent male family members, circles female family members, black symbols family members with multiple-system atrophy, gray symbols family members with Parkinson's disease, open symbols unaffected family members, slashes deceased family members, and small circles family members for whom genomic DNA samples were available. MSA-C denotes multiple-system atrophy of the cerebellar type, MSA-P multiple-system atrophy with predominant parkinsonism, and unclassified MSA-P+C similarly predominant parkinsonian and cerebellar signs.

ANALYSIS OF *COQ2* AND OTHER GENES ASSOCIATED WITH COENZYME Q₁₀

On the basis of linkage analysis and whole-genome sequencing, we sequenced *COQ2* and the other 11 genes involved in the biosynthetic pathway for coenzyme Q₁₀ (*PDSS1*, *PDSS2*, *COQ3*, *COQ4*, *COQ5*,

COQ6, *COQ7*, *ADCK3*, *COQ9*, *COQ10A*, and *COQ10B*), using the Sanger method (Table S3 in the Supplementary Appendix).

We prepared samples of mutant human *COQ2* complementary DNA (cDNA) by means of site-directed mutagenesis (Table S4 in the Supple-

mentary Appendix). A yeast *coq2*-null mutant, the BY4741 Δ *coq2* strain, was transformed with pAUR123 (Takara Bio) containing the nonmutated or mutated human *COQ2* cDNA. We measured the growth rate in a medium with a non-fermentable carbon source by monitoring the optical density of a sample measured at a wavelength of 600 nm (OD_{600}). We used mitochondrial fractions prepared from lymphoblastoid cell lines with the QProteome Mitochondria Isolation Kit (Qiagen) as the enzyme source. *COQ2* activity (Enzyme Commission number, 2.5.1.39) was assayed as described previously.²⁰

COENZYME Q₁₀ LEVEL IN TISSUES

Using high-performance liquid chromatography, we measured levels of coenzyme Q₁₀ (ubiquinone-10 and ubiquinol-10) and free (unesterified) cholesterol in lymphoblastoid cell lines established from 152 patients with multiple-system atrophy and 76 controls and in cerebellum samples obtained on autopsy from 3 patients with multiple-system atrophy and 3 controls.²¹

STATISTICAL ANALYSIS

All results are presented as means and standard deviations. We used Student's *t*-test to evaluate the significance of differences in the mean age at disease onset between carriers and noncarriers of the *COQ2* mutation. We used Fisher's exact test to calculate the significance of the difference in allele frequencies between carriers and noncarriers, with contingency tables and standard methods used to compute odds ratios and corresponding 95% confidence intervals. We used the Kruskal-Wallis test, followed by the Steel test, to perform an analysis of variance. All statistical tests were two-sided, and a *P* value of less than 0.05 was considered to indicate statistical significance.

RESULTS

LINKAGE ANALYSIS OF FAMILIAL DISEASE

Parametric linkage analysis of the six family pedigrees revealed no single locus showing a linkage compatible with autosomal recessive inheritance. However, in the parametric linkage analysis allowing for heterogeneity, we detected several loci showing positive scores for heterogeneity logarithm of the odds (HLOD), indicating that more than one locus was involved in the different multiplex families (Fig. S1B in the Supplementary

Appendix). In particular, two regions on chromosome 4 showed the highest HLOD scores, exceeding 2.0. Results of nonparametric linkage analysis (Fig. S1C in the Supplementary Appendix) were consistent with those of parametric linkage analysis allowing for heterogeneity. Parametric linkage analysis of chromosome 4 in individual pedigrees revealed positive LOD scores in an overlapping region in four families (Family 1, Family 2, Family 4, and Family 12), with Family 1 having the highest LOD score of 1.93 (72.795 to 89.616 Mb) (Fig. S1A and S2A in the Supplementary Appendix). Thus, we selected Family 1 to undergo whole-genome sequencing.

SUSCEPTIBILITY GENE IN FAMILIAL DISEASE

Whole-genome sequencing of a sample obtained from Participant II-4, one of two affected members of Family 1, generated 187.5 Gb of short reads, with an average coverage of 58 \times and 3,492,429 single-nucleotide variants (SNVs) or insertions or deletions. We winnowed the 3,492,429 variants down to 4 by selecting SNVs that were located in the candidate regions defined on linkage analysis in Family 1 (regions with the highest LOD score spanning approximately 80 Mb in total), that were located in exons or splice sites, that were predicted to cause amino acid changes or changes in pre-messenger RNA splicing, and that were not registered in the database of single-nucleotide polymorphisms, build 130 (dbSNP130), indicating that the variants are extremely rare in the general population (Fig. S2B in the Supplementary Appendix). Each of these 4 SNVs is predicted to result in an amino acid substitution: K707R (c.2120A \rightarrow G) in *SHROOM3* (NCBI Reference Sequence, NM_020859.3), M128V (c.382A \rightarrow G) and V393A (c.1178T \rightarrow C) in *COQ2* (NCBI Reference Sequence, NM_015697.7), and R231G (c.691A \rightarrow G) in *SCEL* (NCBI Reference Sequence, NM_144777.2).

In the 180 Japanese control samples, we did not observe the SNV encoding the M128V variant but did observe SNVs encoding K707R in *SHROOM3*, V393A in *COQ2*, and R231G in *SCEL*, which were present on 3, 5, and 98 of 360 alleles, respectively. We therefore considered the SNP encoding M128V in *COQ2*, which encodes parahydroxybenzoate-polyprenyl transferase, an enzyme involved in the biosynthesis of coenzyme Q₁₀, as a candidate variant in conferring susceptibility to familial multiple-system atrophy.

Cosegregation analysis of samples from Family 1 revealed that the two affected family mem-

bers, Participants II-4 and II-8, carried the homozygous M128V-V393A variant in *COQ2*, and the unaffected sibling who was tested (Participant II-7) did not carry this variant (Fig. S2C in the Supplementary Appendix). Mutational analysis of *COQ2* in Family 12 revealed heterozygous mutations consisting of nonsense (R387X, c.1159C→T) and missense (V393A) variants in both affected siblings (Participants II-3 and II-4). Their mother (Participant I-2) was heterozygous for V393A, one unaffected sibling (Participant II-1) lacked this variant, and the other unaffected sibling (Participant II-2) was heterozygous for R387X. R387X was not observed in the 180 Japanese controls.

We did not detect variants of *COQ2* in the other four families (Families 2, 3, 4, and 8). Because *COQ2* encodes an enzyme essential for the biosynthesis of coenzyme Q₁₀, we further sequenced the other 11 genes in the biosynthetic pathway for coenzyme Q₁₀ (*PDSS1*, *PDSS2*, *COQ3*, *COQ4*, *COQ5*, *COQ6*, *COQ7*, *ADCK3*, *COQ9*, *COQ10A*, and *COQ10B*) in the remaining four families and in a previously described multiplex family¹⁴ but did not observe variants that cosegregated with disease.

COQ2 VARIANTS AND SPORADIC DISEASE

To investigate the involvement of *COQ2* variants in sporadic multiple-system atrophy, we extended the mutational analysis of *COQ2* to a Japanese series consisting of 363 patients with multiple-system atrophy and 520 controls. A common *COQ2* variant (rs6818847, predicted to result in an amino acid substitution, V66L (c.196G→T) with allele frequencies of 0.10 and 0.12 in the Japanese patients with multiple-system atrophy and controls, respectively, was not included in further analysis. Four patients with multiple-system atrophy carried two variants simultaneously (one carried an I147T [c.440T→C] and a nonmutated [NM] allele at codon 147 and V393A/NM at codon 393, one had R387Q [c.1160G→A]/NM at codon 387 and V393A/NM at codon 393, and two had V393A/V393A), whereas none of the controls had two variants of *COQ2* (Table 1). Sequencing of the subcloned mutated alleles confirmed that R387Q/V393A was present in a compound heterozygous state. We were unable to determine the phase of I147T/V393A, because the distance between I147T and V393A was too large to be amplified by means of polymerase-chain-reaction (PCR) assay in a single fragment, and samples

Table 1. *COQ2* Variants Found in Patients with Sporadic Multiple-System Atrophy in Japanese, European, and North American Series, as Compared with Controls.*

Genotype	Japanese Series		European Series		North American Series	
	Patients (N=363)	Controls (N=520)	Patients (N=223)	Controls (N=315)	Patients (N=172)	Controls (N=294)
P72L/NM	0	1	0	0	0	0
F79L/NM	0	0	1	0	0	0
P99H†/NM	0	0	0	0	1	0
S107T†/NM	0	0	1	0	0	0
R119H†/NM	0	0	0	0	0	1
I147T‡/V343A§	1	0	0	0	0	0
P157S†/NM	1	0	0	0	0	0
S163F†/NM	1	0	0	0	0	0
T317A‡/NM	0	0	1	0	0	0
S347C‡/NM	0	0	1	0	0	0
N386H/NM	0	1	0	0	0	0
R387Q†/V393A§	1	0	0	0	0	0
V393A§/NM	29	17	0	0	0	0
V393A§/V393A§	2	0	0	0	0	0

* NM denotes nonmutated.

† This variant was deemed to be severely deleterious on yeast complementation assay.

‡ This variant was deemed to be mildly deleterious on yeast complementation assay.

§ This variant had decreased COQ2 activity on enzyme assay.

Table 2. Association between the COQ2 V393A Variant and Sporadic Multiple-System Atrophy in the Japanese Series.*

V343A Variant†	Patients with Multiple-System Atrophy				Patients with Other Neurologic Diseases					
	Patients (N=363)	Tier 1 Controls (N=520)	Comparison with Tier 1 odds ratio (95% CI)	P value	Tier 2 Controls (N=2383)	Comparison with Tier 2 odds ratio (95% CI)	P value	Alzheimer's Disease (N=2728)	Parkinson's Disease (N=659)	ALS (N=634)
Allele frequency — no./total no. (%)	35/726 (4.8)	17/1040 (1.6)	3.05 (1.65–5.85)	1.5×10 ⁻⁴	106/4766 (2.2)	2.23 (1.46–3.32)	6.0×10 ⁻⁵	109/5456 (2.0)	33/1318 (2.5)	31/1268 (2.4)
Heterozygous — no.	31	17			106			105	33	31
Homozygous — no.	2	0			0			2	0	0

* Odds ratios and P values are for the comparisons between patients with multiple-system atrophy and each of the two groups of controls (tier 1 and tier 2). ALS denotes amyotrophic lateral sclerosis, and CI confidence interval.

† In the combined series of Japanese, European, and North American participants, functionally deleterious variants P99H, S107T, R119H, I147T, P157S, S163F, T317A, S347C, and R387Q (as determined on yeast complementation assay) were found in 8 of 1516 alleles (0.53%) in patients with multiple-system atrophy, as compared with 1 of 2258 alleles (0.05%) in controls (odds ratio, 11.97; 95% CI, 1.60 to 531.5; P=0.0004).

of genomic DNA from the parents were unavailable. We found that 29 patients with multiple-system atrophy and 17 controls were heterozygous for the V393A variant. In addition, we detected four novel heterozygous variants: two in patients with multiple-system atrophy (P157S [c.469C→T] and S163F [c.488C→T]) and two in controls (P72L [c.215C→T] and N386H [c.1156A→C]).

Of the COQ2 variants, the V393A variant is relatively common in the Japanese population. As shown in Table 2, we found that the V393A allele occurred in 35 of 726 alleles (4.8%) from Japanese patients with multiple-system atrophy and in 17 of 1040 alleles (1.6%) from Japanese controls (odds ratio for patients with multiple-system atrophy, 3.05; 95% confidence interval [CI], 1.65 to 5.85; P=1.5×10⁻⁴). Genotyping in the second series of 2383 Japanese controls showed that the V393A variant had an allele frequency of 2.2% (106 of 4766 alleles; odds ratio, 2.23; 95% CI, 1.46 to 3.32; P=6.0×10⁻⁵). Genotyping Japanese persons with other neurodegenerative diseases revealed that the V393A allele frequencies were 2.0% (109 of 5456 alleles) among patients with Alzheimer's disease, 2.5% (33 of 1318 alleles) among those with Parkinson's disease, and 2.4% (31 of 1268 alleles) among those with ALS. These allele frequencies did not differ significantly from those in the first or second set of controls, confirming the specificity of the V393A variant in patients with multiple-system atrophy. Two patients with Alzheimer's disease who were found to carry homozygous V393A mutations did not show any signs of parkinsonism, cerebellar ataxia, or autonomic dysfunction.

We then performed genotyping in the European and North American series of patients with multiple-system atrophy. In the European series, we found four singleton COQ2 variants (encoding amino acid substitutions F79L [c.235T→C], S1077T [c.320G→C], T317A [c.949A→G], and S347C [c.1039A→T]) among the patients, whereas none of the controls had any variants in COQ2. In the North American series, we found one variant (P99H [c.296C→A]) in a patient with multiple-system atrophy and one variant (R119H [c.356G→A]) in a control (Table 1). At the time of recruitment for the study, the carrier of R119H, who was 60 years old, had no signs of parkinsonism, cerebellar ataxia, or autonomic dysfunction, but this participant was unavailable for follow-up assessment. Intriguingly, the V393A

variant, a relatively common variant in the Japanese population, was not observed in patients with multiple-system atrophy or controls in either the European or the North American series.

FUNCTIONAL ANALYSIS OF MUTANT COQ2

To determine the functional effect of each variant on the mitochondrial aerobic energy production in which coenzyme Q₁₀ plays an essential




Figure 2. Functional Analysis of COQ2 Variants.

Panel A shows the results of a yeast complementation assay, including the growth curves of the yeast *coq2*-null mutants transformed with the pAUR123 vector containing the nonmutated (NM) human COQ2 complementary DNA (cDNA) or mock vector (subpanel a) and those transformed with the AUR123 vector containing different versions of human COQ2 cDNA (encoding the substitutions V66L, P72L, F79L, N386H, V393A, I147T, T317A, and S347C) (subpanel b). Transformants carrying a COQ2 allele encoding the I147T, T317A, or S347C substitution show considerably lower growth rates than nonmutated COQ2, which still shows a higher growth rate than the *coq2*-null strain (mildly deleterious). Transformants carrying a COQ2 allele encoding the V66L, P72L, F79L, N386H, or V393A substitution show growth rates similar to that of nonmutated COQ2. The *coq2*-null mutants transformed with the pAUR123 vector containing different versions of human COQ2 cDNA (P99H, S107T, R119H, M128V, M128V-V393A, P157S, S163F, R387X, or R387Q) show severely decreased respiration-dependent growth rates, as does the *coq2*-null strain (severely deleterious) (subpanel c). Each yeast strain was pre-grown in yeast extract peptone dextrose (YPD) medium, diluted to an optical density of a sample measured at a wavelength of 600 nm (OD₆₀₀) of 0.1, and then incubated in yeast extract peptone glycerol (YPG) medium at 23°C with shaking at a rate of 200 rotations per minute for 4 days. OD₆₀₀ was measured every 10 minutes. The experiments were conducted in quadruplicate, and the mean OD₆₀₀ was plotted against the incubation time. Panel B shows COQ2 activity in lymphoblastoid cell lines, as determined by measuring the incorporation of radioactive parahydroxybenzoate (PHB) into decaprenyl-PHB. COQ2 activity was measured in lymphoblastoid cell lines from each patient with multiple-system atrophy carrying COQ2 variants (encoding R387Q/V393A, R387X/V393A, V393A/V393A, or V393A/NM) and from a control without variants. The mean values from nine independent experiments are shown. T bars indicate standard deviations. Group comparisons were performed with the use of the Kruskal-Wallis test, followed by the Steel test. Asterisks indicate P<0.05 for the comparison with a control sample (nonmutated COQ2 genotype). Panel C shows intracellular levels of coenzyme Q₁₀ in frozen cerebellum samples obtained from three patients with multiple-system atrophy (one who was homozygous for M128V-V393A and two who were heterozygous for V393A) and from three controls. Brain-tissue samples weighing approximately 100 mg were homogenized in 10 volumes (volume to weight) of 10 mM TRIS-hydrochloric acid (with a pH of 7.4) containing 0.32 M sucrose, 1 mM ethylenediaminetetraacetic acid (EDTA), and 20% sodium dodecyl sulfate (SDS). Coenzyme Q₁₀ was then extracted with hexane and ethanol (in a 5:2 ratio according to volume), and the extract was subjected to high-performance liquid chromatography to measure the level of coenzyme Q₁₀, after adjustment for the free (unesterified) cholesterol level.²¹

role in the electron transfer, we carried out functional complementation analysis by transforming the yeast *coq2*-null strain with nonmutated or mutated human COQ2 cDNA (Fig. 2A). Transformants of the BY4741 Δ *coq2* yeast strain with the mutated COQ2, including transformants separately carrying the P99H, S107T, R119H, M128V, M128V-V393A, P157S, S163F, R387Q, and R387X alleles, showed severely decreased growth rates, similar to those observed in the *coq2*-null strain. In addition, transformants with mutated COQ2, including those with the variants encoding the I147T, T317A (c.949A→G), and S347C (c.1039A→T) substitutions, showed substantially lower growth rates than those expressing nonmutated COQ2, which had a higher growth rate than the *coq2*-null strain (mildly deleterious). The transformants with mutated COQ2, including transformants separately carrying the V66L, P72L, F79L, N386H, and V393A alleles, showed growth rates similar to those of the transformants expressing nonmutated COQ2. As described above, the yeast strain with M128V-V393A identified in Family 1 showed a severely decreased growth rate, whereas the strain with V393A had a growth rate similar to that of nonmutated COQ2, indicating that of the two variants, M128V primarily contributed to the impairment in COQ2 function.

Focusing on the rare variants that were identified in the case-control series (Table 1), we found that nine variants (P99H, S107T, R119H, I147T, P157S, S163F, T317A, S347C, and R387Q) were mildly or severely deleterious. On combining all three series, eight variants (P99H, S107T, I147T, P157S, S163F, T317A, S347C, and R387Q) were identified in 758 patients with multiple-system atrophy, whereas only one variant (R119H) was found in 1129 controls (odds ratio, 11.97; 95% CI, 1.60 to 531.52; $P=0.004$) (Table 2 footnote). Yeast complementation analysis showed that the F79L variant, identified in a European patient with multiple-system atrophy, did not impair the growth rate. Lymphoblastoid cell lines from this patient were unavailable for further measurement of the activity of mutant COQ2, thus making it difficult to interpret the pathogenicity of this variant.

COQ2 ACTIVITIES IN LYMPHOBLASTOID CELL LINES

We measured COQ2 activities in lymphoblastoid cell lines from patients carrying COQ2 mutations, when available. We focused on the V393A variant because it is commonly associated with multiple-

system atrophy and showed an apparently normal growth rate in the yeast complementation assay. We determined COQ2 activities in lymphoblastoid cell lines with COQ2 variants R387Q/V393A, R387X/V393A, V393A/V393A, or V393A/NM and in a control without variants. The COQ2 activities in the lymphoblastoid cell lines (V393A/NM) obtained from patients with multiple-system atrophy were significantly lower than those in the control cell lines. The COQ2 activities in the cell lines from patients with multiple-system atrophy carrying two mutated COQ2 alleles were further decreased (Fig. 2B).

CORRELATIONS BETWEEN GENOTYPE AND PHENOTYPE

The clinical features of patients with sporadic multiple-system atrophy carrying deleterious COQ2 variants (as determined on yeast complementation assay and COQ2-activity measurement) and those of noncarriers are summarized in Table S5 in the Supplementary Appendix. The mean age at the onset of multiple-system atrophy among carriers was older than that among noncarriers ($P=0.002$). Among carriers, 34 had subtype C and 5 had subtype P. Among noncarriers, 468 had subtype C and 209 had subtype P. The subtype was unclassified in 42 noncarriers. The ratio of the number of patients with subtype C to the number with subtype P was significantly higher among carriers of COQ2 variants than among noncarriers ($P=0.02$).

INTRACELLULAR COENZYME Q₁₀ IN LYMPHOBLASTOID CELL LINES

We measured intracellular coenzyme Q₁₀ levels in lymphoblastoid cell lines from patients with multiple-system atrophy and controls. The participants were grouped as follows: 3 patients with multiple-system atrophy carrying two variants (R387Q/V393A, R387X/V393A, and V393A/V393A), 16 patients carrying heterozygous V393A, 133 patients without variants, and 76 controls without COQ2 variants (Table 3). Intracellular levels of coenzyme Q₁₀ in lymphoblastoid cell lines from patients with multiple-system atrophy who carried two variant alleles were substantially lower than levels in cell lines from controls without variants. Intracellular coenzyme Q₁₀ levels in patients who were heterozygous for V393A and in those without COQ2 variants were not significantly lower than levels in controls without COQ2 variants.

Table 3. Intracellular Levels of Coenzyme Q₁₀ in Lymphoblastoid Cell Lines, According to COQ2 Variant.*

Variable	Patients with Multiple-System Atrophy				Controls	
	R387Q/V393A	R387X/V393A	V393A/V393A	V393A/NM	NM/NM	NM/NM
No. of participants with variant	1	1	1	16	133	76
Ratio of coenzyme Q ₁₀ to free (unesterified) cholesterol†	2.19	2.58	1.86	3.38±0.53	3.41±0.74	3.48±0.75
Coenzyme Q ₁₀ level as a percentage of mean value in controls — %‡	62.9	74.1	53.4	97.1	98.0	100.0

* Plus–minus values are means ±SD. NM denotes nonmutated.

† The ratio of coenzyme Q₁₀ to free (unesterified) cholesterol reflects the intracellular level of coenzyme Q₁₀. Lower values indicate decreased levels of intracellular coenzyme Q₁₀, presumably reflecting decreased biosynthesis of coenzyme Q₁₀. To calculate the ratio, coenzyme Q₁₀ was measured in nanomoles per liter and free cholesterol in micromoles per liter.

‡ Lower values indicate decreased levels of intracellular coenzyme Q₁₀, as compared with the mean value in controls, presumably reflecting decreased biosynthesis of coenzyme Q₁₀.

COENZYME Q₁₀ IN BRAIN TISSUE

Only a limited number of brain-tissue samples from patients with multiple-system atrophy carrying COQ2 variants were available. Nevertheless, we measured coenzyme Q₁₀ in frozen brain tissues from three patients with COQ2 variants (one patient who was homozygous for M128V-V393A and two patients with V393A/NM) and from three controls without COQ2 variants (Fig. 2C). The levels of coenzyme Q₁₀ in patients who were homozygous for M128V-V393A were substantially lower than the levels in controls.

DISCUSSION

We identified homozygous or compound heterozygous COQ2 mutations in two of the six multiplex families with multiple-system atrophy, a finding that suggests a role of these mutations in the pathogenesis of familial disease. We further found that functionally impaired variants in COQ2 were associated with an increased risk of sporadic disease. In familial cases of multiple-system atrophy, linkage analysis strongly indicated locus heterogeneity in these families, and the identification of the causal variants in the remaining four families will require analyses such as whole-genome sequencing.

We found that a common variant (V393A) and multiple rare variants in COQ2 were associated with sporadic multiple-system atrophy. The V393A variant was found exclusively in the Japanese participants, with an allele frequency of 1.6 to 2.2%. The allele frequency of V393A in patients with multiple-system atrophy (4.8%) was significantly

higher than that in controls (1.6 to 2.2%) with odds ratios of 2.23 to 3.05. The modest risk of multiple-system atrophy that was associated with the common variant V393A suggests that V393A is a susceptibility factor rather than a causal factor for this disease. The odds ratio for the presence of deleterious rare variants was 11.97, which is much larger than that for V393A. Nonetheless, we should consider that these heterozygous variants in COQ2 are not necessarily causal but rather confer a strong susceptibility to sporadic multiple-system atrophy. Members of Family 1 and Family 12 who carried deleterious variants in the heterozygous state did not have clinical signs of multiple-system atrophy.

The ratio of patients with subtype C multiple-system atrophy to those with subtype P was higher among carriers of deleterious COQ2 variants than among noncarriers, which suggests that the cerebellum is more vulnerable to compromised COQ2 function than other regions of the central nervous system. Of the COQ2 variants that we detected, the V393A variant was the most prevalent and was exclusively found in Japanese participants. These findings may in part explain the clinical observations that subtype C is more prevalent than subtype P in the Japanese population⁹ but not in the European population¹¹ or the North American population.¹² However, there were only 35 carriers of deleterious COQ2 variants among 363 patients with multiple-system atrophy in the Japanese case series. In addition, the clinical presentations of the two patients with familial disease who had the highest mutational load were different: subtype P in the patients in Fam-

ily 1 and subtype C in the patients in Family 12. Thus, the genotypes of *COQ2* do not fully explain the clinical phenotypes.

Previous studies have shown evidence of mitochondrial respiratory-chain dysfunction or oxidative injury in patients with multiple-system atrophy.²²⁻²⁴ The combination of oxidative stress and overexpression of oligodendroglial α -synuclein has been reported to replicate the characteristics of this disease.²⁵⁻²⁸ Our findings suggest that impaired *COQ2* activity, which would be predicted to impair the mitochondrial respiratory chain and increase vulnerability to oxidative stress, causes susceptibility to multiple-system atrophy. A primary deficiency of coenzyme Q₁₀ that is caused by *COQ2* mutations has been described as an infantile-onset multisystem disorder and a nephropathy in several families.^{29,30} The clinical presentation of these affected family members, however, differed markedly from the presentations of patients with multiple-system atrophy, perhaps because the decrease in *COQ2* activity associated with the mutations in patients with multiple-system atrophy appears to be milder than that observed in patients with a primary deficiency of coenzyme Q₁₀.

Previous approaches to identifying susceptibility genes have used genomewide association studies or candidate-gene approaches.³¹⁻³³ Our identification of rare *COQ2* variants was accomplished by starting with multiplex families and then extending the analysis to patients with sporadic multiple-system atrophy, reflecting an alternative approach to the elucidation of genetic variants with strong effect sizes in an apparently nongenetic disorder.³⁴

From the therapeutic viewpoint, oral supplementation with coenzyme Q₁₀ may be helpful in treating multiple-system atrophy, particularly for patients with susceptibility-conferring *COQ2* variants. The safety and side-effect profile of high-dose supplementation with coenzyme Q₁₀ have been well established.^{35,36}

ADDENDUM

Human *COQ2* contains four ATG codons in exon 1. Among the four potential translation initiation codons in exon 1, the protein isoform starting at the fourth ATG codon has been adopted as the canonical sequence of the *COQ2* protein in the UniProt database (Q96H96, <http://www.uniprot.org/uniprot/Q96H96>). In this study, we focused entirely on *COQ2* variants after the fourth ATG codon.

Supported in part by grants from the Japan Society for the Promotion of Science (KAKENHI) (22129001 and 22129002, to Dr. Tsuji); the Ministry of Health, Labor, and Welfare of Japan (1123-Jitsuyoka [Nanbyo]-Ippan-004, to Dr. Tsuji); the Japanese Ministry of Education, Culture, Sports, Science, and Technology; the French Agency for Research (ANR-09-MNPS-032-01/R09148DS, to Drs. Dürr and Brice); Programme Hospitalier de Recherche Clinique (AOM03059/R05129DD, to Drs. Dürr and Brice); Deutsche Forschungsgemeinschaft (Wu 184-6, to Dr. Wüllner); and Deutsche Parkinson Vereinigung (to Dr. Wüllner).

Disclosure forms provided by the authors are available with the full text of this article at [NEJM.org](http://www.nejm.org).

We thank the staff members of the Radioisotope Center at the University of Tokyo; Keiko Hirayama, Zhenghong Wu, and Mio Takeyama for their support in laboratory experiments; Dr. Kazuyuki Tao, Shinya Uchino, and Manabu Seki for their technical help; Dr. Cecilia Marelli for her clinical input; Drs. Yoshinori Kajimoto and Kokoro Ozaki for providing DNA samples and clinical information; and the DNA and Cell Bank of Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM) in Paris for technical assistance.

APPENDIX

The members of the Multiple System Atrophy Research Collaboration are as follows: Jun Mitsui, M.D., Ph.D., Takashi Matsukawa, M.D., and Hiroyuki Ishiura, M.D., Ph.D., Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo; Yoko Fukuda, Ph.D., Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo, and Max-Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany; Yaeko Ichikawa, M.D., Ph.D., Hidetoshi Date, Ph.D., Budrul Ahsan, Ph.D., Yasuo Nakahara, M.D., Ph.D., Yoshio Momose, M.D., Ph.D., Yuji Takahashi, M.D., Ph.D., Atsushi Iwata, M.D., Ph.D., and Jun Goto, M.D., Ph.D., Department of Neurology, Graduate School of Medicine, University of Tokyo, Tokyo; Yorihiro Yamamoto, Ph.D., School of Bioscience and Biotechnology, Tokyo University of Technology, Tokyo; Makiko Komata, Ph.D., and Katsuhiko Shirahige, Ph.D., Center for Epigenetic Disease, Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo; Kenju Hara, M.D., Ph.D., Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan; Akiyoshi Kakita, M.D., Ph.D., Mitsunori Yamada, M.D., Ph.D., and Hitoshi Takahashi, M.D., Ph.D., Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan; Osamu Onodera, M.D., Ph.D., and Masatoyo Nishizawa, M.D., Ph.D., Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan; Hiroshi Takashima, M.D., Ph.D., Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan; Ryozyo Kuwano, M.D., Ph.D., Department of Molecular Genetics, Center for Bioresources, Brain Research Institute, Niigata University, Niigata, Japan; Hirohisa Watanabe, M.D., Ph.D., Mizuki Ito, M.D., Ph.D., and Gen Sobue, M.D., Ph.D., Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Hiroyuki Soma, M.D., Ph.D., Ichiro Yabe, M.D., Ph.D., and Hidenao Sasaki, M.D., Ph.D., Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Masashi Aoki, M.D., Ph.D., Department of Neurology, Tohoku University School of Medicine, Sendai, Japan; Kinya Ishikawa, M.D., Ph.D., and Hidehiro Mizusawa, M.D., Ph.D., Department of Neurology and Neurological Science, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo; Kazuaki Kanai, M.D., Ph.D., Takamichi Hattori, M.D., Ph.D., and Satoshi Kuwabara, M.D., Ph.D., Department of Neurology, Chiba University School of Medicine, Chiba, Japan; Kimihito Arai, M.D., Ph.D., Division of Neurology, National Hospital Organization, Chiba East Hospital,

Chiba, Japan; Shigeru Koyano, M.D., Ph.D., Department of Clinical Neurology and Stroke Medicine, Graduate School of Medicine, Yokohama City University, Yokohama, Japan; Yoshiyuki Kuroiwa, M.D., Ph.D., Department of Neurology, Teikyo University School of Medicine University Hospital, Mizonokuchi, Kawasaki, Japan; Kazuko Hasegawa, M.D., Ph.D., Division of Neurology, National Hospital Organization, Sagami National Hospital, Sagami, Japan; Tatsuhiko Yuasa, M.D., Ph.D., Department of Neurology, Kamagaya-Chiba Medical Center for Intractable Neurological Disease, Kamagaya General Hospital, Chiba, Japan; Kenichi Yasui, M.D., Ph.D., and Kenji Nakashima, M.D., Ph.D., Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan; Hijiri Ito, M.D., Ph.D., Department of Neurology, Mifukai Vihara Hananosato Hospital, Hiroshima, Japan; Yuishin Izumi, M.D., Ph.D., and Ryuji Kaji, M.D., Ph.D., Department of Clinical Neuroscience, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan; Takeo Kato, M.D., Ph.D., Departments of Neurology, Hematology, Metabolism, Endocrinology, and Diabetology, Faculty of Medicine, Yamagata University, Yamagata, Japan; Susumu Kusunoki, M.D., Ph.D., Department of Neurology, Kinki University School of Medicine, Osaka, Japan; Yasushi Osaki, M.D., Ph.D., Department of Geriatrics, Cardiology and Neurology, Kochi Medical School, Nankoku, Japan; Masahiro Horiuchi, M.D., Ph.D., Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan; Tomoyoshi Kondo, M.D., Ph.D., Department of Neurology, Wakayama Medical University, Wakayama, Japan; Shigeo Murayama, M.D., Ph.D., Department of Neuropathology and the Brain Bank for Aging Research, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo; Nobutaka Hattori, M.D., Ph.D., Department of Neurology, Juntendo University School of Medicine, Tokyo; Mitsutoshi Yamamoto, M.D., Ph.D., Department of Neurology, Kagawa Prefectural Central Hospital, Takamatsu, Japan; Miho Murata, M.D., Ph.D., Department of Neurology, National Center Hospital of Neurology and Psychiatry, Tokyo; Wataru Satake, M.D., Ph.D., and Tatsushi Toda, M.D., Ph.D., Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan; Alexandra Dürr, M.D., Ph.D., and Alexis Brice, M.D., INSERM, UMR_S975, CRICM, F-75013, Paris, UPMC University of Paris 06, UMR_S975, F-75013, Paris, CNRS UMR 7225, F-75013, Paris, and Hôpital de la Salpêtrière, Département de Génétique et Cytogénétique, F-75013, Paris; Alessandro Filla, M.D., Department of Neurological Sciences, University Federico II, Naples, Italy; Thomas Klockgether, M.D., and Ullrich Wüllner, M.D., Ph.D., Department of Neurology, University of Bonn and German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; Garth Nicholson, M.B., B.S., Ph.D., University of Sydney at the Australian and New Zealand Army Corps (ANZAC) Research Institute, Concord Hospital, Sydney; Sid Gilman, M.D., Department of Neurology, University of Michigan, Ann Arbor; Clifford W. Shults, M.D.,* Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla; Caroline M. Tanner, M.D., Ph.D., Parkinson's Institute, Sunnyvale, CA; Walter A. Kukull, M.D., Department of Epidemiology, University of Washington School of Public Health, Seattle; Virginia M.-Y. Lee, Ph.D., Institute on Aging, Udall Parkinson's Research Center, Center for Neurodegenerative Disease Research and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Eliezer Masliah, M.D., Department of Neurosciences, University of California San Diego, San Diego; Phillip A. Low, M.D., and Paola Sandroni, M.D., Ph.D., Department of Neurology, Mayo Clinic, Rochester, MN; John Q. Trojanowski, M.D., Ph.D., Institute on Aging, Udall Parkinson's Research Center, Center for Neurodegenerative Disease Research and the Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Laurie Ozelius, Ph.D., Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York; Tatiana Foroud, Ph.D., Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indiana Alcohol Research Center, Indianapolis; and Shoji Tsuji, M.D., Ph.D., Department of Neurology, Graduate School of Medicine and Medical Genome Center, University of Tokyo, Tokyo.

*Deceased.

REFERENCES

- Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. *J Neurol Neurosurg Psychiatry* 1969;32:28-34.
- Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. *Ann Neurol* 1998;44:415-22.
- Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. *Neurosci Lett* 1998;249:180-2.
- Arima K, Ueda K, Sunohara N, et al. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. *Acta Neuropathol* 1998;96:439-44.
- Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. *Neurosci Lett* 1998;251:205-8.
- Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). *J Neurol Sci* 1989;94:79-100.
- Nakazato Y, Yamazaki H, Hirato J, Ishida Y, Yamaguchi H. Oligodendroglial microtubular tangles in olivopontocerebellar atrophy. *J Neuropathol Exp Neurol* 1990;49:521-30.
- Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology* 2008;71:670-6.
- Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. *Brain* 2002;125:1070-83.
- Tsuji S, Onodera O, Goto J, Nishizawa M. Sporadic ataxias in Japan — a population-based epidemiological study. *Cerebellum* 2008;7:189-97.
- Geser F, Seppi K, Stampfer-Kountchev M. The European Multiple System Atrophy-Study Group (EMSA-SG). *J Neural Transm* 2005;112:1677-86.
- May S, Gilman S, Sowell BB, et al. Potential outcome measures and trial design issues for multiple system atrophy. *Mov Disord* 2007;22:2371-7.
- Hara K, Momose Y, Tokiguchi S, et al. Multiplex families with multiple system atrophy. *Arch Neurol* 2007;64:545-51.
- Wüllner U, Schmitt I, Kammal M, Kretschmar HA, Neumann M. Definite multiple system atrophy in a German family. *J Neurol Neurosurg Psychiatry* 2009;80:449-50.
- Hohler AD, Singh VJ. Probable hereditary multiple system atrophy-autonomic (MSA-A) in a family in the United States. *J Clin Neurosci* 2012;19:479-80.
- Fukuda Y, Nakahara Y, Date H, et al. SNP HiTLINK: a high-throughput linkage analysis system employing dense SNP data. *BMC Bioinformatics* 2009;10:121.
- Gudbjartsson DF, Thorvaldsson T, Kong A, Gunnarsson G, Ingólfsson A. Allegro version 2. *Nat Genet* 2005;37:1015-6.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009;25:1754-60.
- Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 2009;25:2078-9.
- Burón MI, Hermán MD, Alcalá FJ, Villalba JM. Stimulation of polyprenyl

- 4-hydroxybenzoate transferase activity by sodium cholate and 3-[(cholamidopropyl)dimethylammonio]-1-propanesulfonate. *Anal Biochem* 2006;353:15-21.
21. Yamashita S, Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. *Anal Biochem* 1997;250:66-73.
22. Blin O, Desnuelle C, Rascol O, et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. *J Neurol Sci* 1994;125:95-101.
23. Martinelli P, Giuliani S, Lodi R, Iotti S, Zaniol P, Barbiroli B. Failure of brain and skeletal muscle energy metabolism in multiple system atrophy shown by in vivo phosphorous MR spectroscopy. *Adv Neurol* 1996;69:271-7.
24. Yamashita T, Ando Y, Obayashi K, et al. Oxidative injury is present in Purkinje cells in patients with olivopontocerebellar atrophy. *J Neurol Sci* 2000;175:107-10.
25. Stefanova N, Reindl M, Neumann M, et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. *Am J Pathol* 2005;166:869-76.
26. Stefanova N, Georgievska B, Eriksson H, Poewe W, Wenning GK. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. *Neurotox Res* 2012;21:393-404.
27. Ubhi K, Lee PH, Adame A, et al. Mitochondrial inhibitor 3-nitropropionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. *J Neurosci Res* 2009;87:2728-39.
28. Ubhi K, Rockenstein E, Mante M, et al. Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy. *Neuroreport* 2010;21:457-62.
29. López-Martín JM, Salviati L, Trevisson E, et al. Missense mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine synthesis. *Hum Mol Genet* 2007;16:1091-7.
30. Diomedei-Camassei F, Di Giandomenico S, Santorelli FM, et al. COQ2 nephropathy: a newly described inherited mitochondrialopathy with primary renal involvement. *J Am Soc Nephrol* 2007;18:2773-80.
31. Sasaki H, Emi M, Iijima H, et al. Copy number loss of (src homology 2 domain containing)-transforming protein 2 (SHC2) gene: discordant loss in monozygotic twins and frequent loss in patients with multiple system atrophy. *Mol Brain* 2011;4:24.
32. Al-Chalabi A, Dürr A, Wood NW, et al. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. *PLoS One* 2009;4(9):e7114.
33. Scholz SW, Houlden H, Schulte C, et al. SNCA variants are associated with increased risk for multiple system atrophy. *Ann Neurol* 2009;65:610-4. [Erratum, *Ann Neurol* 2010;67:277.]
34. Tsuji S. Genetics of neurodegenerative diseases: insights from high-throughput resequencing. *Hum Mol Genet* 2010;19:R65-R70.
35. Ferrante KL, Shefner J, Zhang H, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. *Neurology* 2005;65:1834-6.
36. Hyson HC, Kiebertz K, Shoulson I, et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. *Mov Disord* 2010;25:1924-8.

Copyright © 2013 Massachusetts Medical Society.

JOURNAL ARCHIVE AT NEJM.ORG

Every article published by the *Journal* is now available at NEJM.org, beginning with the first article published in January 1812. The entire archive is fully searchable, and browsing of titles and tables of contents is easy and available to all. Individual subscribers are entitled to free 24-hour access to 50 archive articles per year. Access to content in the archive is available on a per-article basis and is also being provided through many institutional subscriptions.



NIH Public Access

Author Manuscript

Published in final edited form as:

Ann Neurol. 2009 May ; 65(5): 610–614. doi:10.1002/ana.21685.

SNCA Variants Are Associated with Increased Risk for Multiple System Atrophy

Sonja W. Scholz, MD^{1,2}, Henry Houlden, MD, PhD, MRCP², Claudia Schulte³, Manu Sharma, PhD³, Abi Li, BSc², Daniela Berg, MD³, Anna Melchers, MD², Reema Paudel, MSc², J. Raphael Gibbs, BS^{1,2}, Javier Simon-Sanchez, PhD¹, Coro Paisan-Ruiz, PhD², Jose Bras, MS¹, Jinhui Ding, PhD¹, Honglei Chen, MD, PhD⁴, Bryan J. Traynor, MD, MMSc, MRCPI¹, Sampath Arepalli, BS¹, Ryan R. Zonozi, BA¹, Tamas Revesz, MD, FRCPATH², Janice Holton, MD, PhD, FRCPATH², Nick Wood, MD, PhD, FRCP², Andrew Lees, MD, FRCP², Wolfgang Oertel, MD⁵, Ullrich Wüllner, MD, PhD⁶, Stefano Goldwurm, MD, PhD⁷, Maria Teresa Pellecchia, MD, PhD^{8,9}, Thomas Illig, PhD, Olaf Riess, MD, PhD¹⁰, Hubert H. Fernandez, MD¹¹, Ramon L. Rodriguez, MD¹¹, Michael S. Okun, MD¹¹, Werner Poewe, MD¹², Gregor K. Wenning, MD, PhD¹², John A. Hardy, PhD, MD (Hon), FMedSci², Andrew B. Singleton, PhD¹, and Thomas Gasser, MD³

¹Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD

²Department of Molecular Neuroscience and Reta Lila Weston Laboratories, Institute of Neurology, University College London, London, United Kingdom

³Hertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany

⁴Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC

⁵Centre of Nervous Diseases, Philipps-University of Marburg, Marburg, Germany

⁶Department of Neurology, University Hospital of Bonn Medical Center, Bonn, Germany

⁷Parkinson Institute, Istituti Clinici di Perfezionamento, Milano, Italy

⁸Department of Neurological Sciences, University Federico II, Napoli, Italy

⁹Institute of Epidemiology, German Research Center for Environmental Health, Helmholtz Zentrum Munchen, Munich, Germany

¹⁰Department of Medical Genetics, Institute of Human Genetics, University of Tuebingen, Tuebingen, Germany

¹¹Department of Neurology and Neurosurgery, University of Florida, Gainesville, FL

¹²Department of Neurology, Medical University Innsbruck, Innsbruck, Austria

Abstract

To test whether the synucleinopathies Parkinson's disease and multiple system atrophy (MSA) share a common genetic etiology, we performed a candidate single nucleotide polymorphism (SNP) association study of the 384 most associated SNPs in a genome-wide association study of Parkinson's disease in 413 MSA cases and 3,974 control subjects. The 10 most significant SNPs

Corresponding author: Dr Scholz, Laboratory of Neurogenetics, National Institute on Aging, 35 Convent Drive, Room 1A-1014, 20892 Bethesda, MD. scholzs@mail.nih.gov.
S.W.S., H.H., C.S., and M.S. contributed equally to this work. A.B.S. and T.G. are joint last authors.

\$watermark-text

\$watermark-text

\$watermark-text

were then replicated in additional 108 MSA cases and 537 controls. SNPs at the SNCA locus were significantly associated with risk for increased risk for the development of MSA (combined $p = 5.5 \times 10^{12}$; odds ratio 6.2).

Introduction

Multiple system atrophy (MSA) and Parkinson's disease (PD) are progressive neurodegenerative disorders characterized neuropathologically by deposition of abnormally phosphorylated α -synuclein. In PD, the aggregates are typically found in neurons as Lewy bodies, whereas in MSA, α -synuclein is deposited predominantly in the form of glial cytoplasmic inclusions.¹ These observations suggest that PD and MSA share a common pathogenic mechanism.

Although MSA appears to occur sporadically in the community, a number of recent observations have implicated genetic factors in the pathogenesis of the disease. First, neurological signs of parkinsonism are more common in relatives of MSA patients.^{2,3} Second, affected members within families with SNCA duplication or triplication manifest clinical and pathological features similar to MSA.⁴⁻⁶ Lastly, there are reports of MSA occurring within families, typically with an autosomal recessive inheritance pattern.^{7,8}

We recently completed a genome-wide association study of 1,713 white PD cases and 3,974 white control subjects. Based on this initial cohort, 384 single nucleotide polymorphisms (SNPs) that were most associated with increased risk for development of PD were selected for further testing in an additional cohort of PD cases and control subjects, and we have presented these findings separately.⁹ To test the hypothesis that MSA and PD share a common genetic causative factor, we tested the same 384 SNPs identified by our PD genome-wide association study in 413 MSA cases and 3,974 healthy control subjects. To confirm our findings, we then replicated the 10 most significant SNPs from this initial screening of MSA cases in an additional cohort of 108 MSA cases and 537 healthy control subjects. Our analysis demonstrated that genetic variants at the SNCA locus coding for α -synuclein were highly significantly associated with increased risk for development of MSA.

Subjects and Methods

Samples

The initial screening cohort consisted of 413 white MSA cases and 3,974 white healthy control subjects. The cases were a mixture of pathologically certain MSA patients ($n = 99$) and clinically probable or possible cases ($n = 314$). A total of 283 of 413 MSA cases were included from collaborating centers of the European MSA study group (www.emsa-sg.org). The replication stage was composed of an independent cohort of 108 clinically probable white MSA cases and 537 white healthy control subjects. Diagnosis of patients was based on consensus criteria that Gilman and colleagues¹⁰ established. Clinical features and collection sites of cases and control subjects are described in Supplemental Tables 1 and 2. The study was approved by each respective institutional review board, and written informed consent was obtained for each participant.

Genotyping

Genotyping of the 384 SNPs selected for the initial screening stage was performed using custom-made GoldenGate assays on a Veracode platform as per the manufacturer's instructions (Illumina, San Diego, CA). Raw genotype data were analyzed using Beadstudio software (version 3.1.0; Illumina).

For the replication stage, genotyping was performed by polymerase chain reaction followed by direct sequencing on an ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, CA) (primer sequences listed in Supplemental Table 3). Genotype information for the control cohort used in the replication stage was extracted from publicly available data of 537 British healthy control subjects who had been previously genotyped on Illumina 610Y SNP chips.

Statistical Analysis

Statistical analysis was performed using PLINK software (v1.04).¹¹ For the screening stage, samples with a call rate less than 90% were excluded from analysis ($n = 13$ cases and 83 control subjects), SNPs with a minor allele frequency less than 0.01 ($n = 3$), SNPs with significant departure from Hardy–Weinberg equilibrium ($p = 0.001$; $n = 29$), SNPs with a missingness rate greater than 5% ($n = 26$), or SNPs with inaccurate clustering ($n = 2$) were excluded from analysis (15 SNPs failed more than one quality-control criterion). Each of the remaining 339 SNPs was then tested for association under allelic, genotypic, dominant, recessive, and trend models, and the lowest p value was calculated for each SNP (p_{min}). Applying the Bonferroni method to correct for multiple testing, the threshold p value for significance was 2.6×10^{-5} (two-sided α of 0.05 divided by [384 SNPs multiplied by 5 models]).

For the replication stage, one SNP was excluded because of departure from Hardy–Weinberg equilibrium in control subjects ($p = 0.01$). The remaining SNPs were tested for association under a recessive model, because this model was the best fit in the screening stage. Based on Bonferroni correction for multiple testing, a p value less than 0.005 was considered significant (two-sided α of 0.05 divided by 10 SNPs tested). The power of this cohort to replicate loci at this significance level with the odds ratios observed in the screening stage is shown in Supplemental Figure 2.

Results

Screening Stage

A total of 384 SNPs were genotyped in a cohort of 413 MSA cases and 3,974 control subjects. After quality-control filters were applied, 339 SNPs were tested for association with disease in a final dataset of 400 cases and 3,891 control subjects under allelic, genotypic, dominant, recessive, and trend models (results of the screening stage are shown in the Table and in Supplemental Figure 1).

Replication Stage

To replicate these findings, we genotyped the 10 most significantly associated SNPs identified in the screening stage in an independent, additional cohort of 108 MSA samples and 537 control samples (see the Table1). Sequence analysis demonstrated a likely genotyping error for rs10515822; reexamination of cluster plots confirmed this error, and this SNP was removed from further analysis. Applying a recessive model, we observed highly significant associations exceeding the Bonferroni threshold for two of these SNPs, namely, rs11931074 ($p = 1.6 \times 10^{-4}$) and rs3857059 ($p = 1.3 \times 10^{-6}$). When data from the replication stage were combined with data from the screening stage, the p value for rs11931074 was 5.5×10^{-12} (odds ratio for homozygous risk allele carriers = 6.2 [95% confidence interval [CI]: 3.4–11.2]), and for rs3857059 was 2.1×10^{-10} (odds ratio for homozygous risk allele carriers = 5.9 [95% CI: 3.2–10.9]) (see Supplemental Table 4 for details). These two SNPs are in complete linkage disequilibrium ($r^2 = 1.0$ in the Centre d'Etude du Polymorphisme Humain HapMap population from Utah), and lie in intron 4 of SNCA (rs3857059) and downstream of SNCA (rs11931074) (Fig1). None of the remaining eight SNPs reached significance in the replication stage or in the combined analysis.

Analysis of Pathology-Proved Multiple System Atrophy Cases

To exclude the possibility that PD cases mistakenly clinically diagnosed as MSA might be falsely driving the association with SNCA, we analyzed the SNPs rs11931074 and rs3857059 in pathology-proven MSA cases and healthy control subjects ($n = 92$ cases and 3,891 control subjects after quality-control filtering). Both SNPs remained significantly associated with increased risk for development of MSA (recessive model p value for rs11931074 = 1.4×10^{-11} ; p value for rs3857059 = 4.9×10^{-6} ; see Supplemental Table 5).

Analysis of Clinical Multiple System Atrophy Subtypes

From available records, 136 patients could be unequivocally assigned to the MSA-P subtype, and 75 patients were MSA-C cases (see Supplemental Table 2 for further details on these cohorts). An analysis in these subgroups could not detect the association between SNCA variants and increased risk for development of MSA (MSA-P: rs11931074, $p = 0.194$; rs3857059, $p = 0.183$; MSA-C: rs11931074, $p = 0.075$; rs3857059, $p = 0.069$; recessive model using Fisher's exact test), probably because of lack of power in the relatively small subgroups. However, this result also suggests that the association is not driven just by one MSA sub-phenotype.

Discussion

In this study, we have demonstrated that genetic variants within the SNCA locus are associated with increased risk for development of MSA. These data represent the first genetic variants convincingly identified for patients with MSA. This study is important in that genetic factors play a greater role in the pathogenesis of MSA, which entity primarily suggests thought of as sporadic in occurrence. The veracity of our findings is underscored by the strength of the association that clearly exceeded the conservative Bonferroni threshold for statistical significance, by the successful replication of our findings in an independent cohort, and by the role that SNCA is already known to play in the disease process based on neuropathological findings.⁴⁻⁶

Previous studies (including sequencing of SNCA coding sequence, gene dosage measurements, microsatellite testing, and haplotype studies) have failed to identify significant association of SNCA variants with MSA.¹²⁻¹⁶ These negative results can be explained by the smaller sample sizes of these studies, and by the fact that none of the SNCA risk variants identified in our study was tested. Our replication of the association between SNCA variants and MSA in an independent patient and control cohort indicates that population stratification was unlikely to be falsely driving the finding. The failure to replicate our findings in MSA-P and MSA-C clinical subgroups was likely due to small sample size and the diagnostic uncertainty inherent to clinical criteria.¹⁷ A combination of these factors would negatively impact the power to detect association within these patient subsets, and studies of larger cohorts will be required to dissect the true pathogenic role of SNCA variants within each of these clinical categories. In contrast, analysis in the smaller, but diagnostically accurate, subset of pathology-proven MSA cases clearly demonstrates that SNCA variants are associated with increased risk for disease.

The significant associations with increased risk for MSA were most clearly observed under the recessive model. However, it is possible that the relatively small size of our case-control cohort was powered only to identify individuals carrying two risk alleles, but that an undetected additive risk at these loci exists. Additional studies involving larger patient cohorts are required to determine whether persons with a single copy of the risk allele are at increased risk for development of MSA.

How does genetic variation at the SNCA locus confer an increased risk for development of MSA? Previous sequence analysis of SNCA coding sequence failed to identify pathogenic mutations; thus, direct alteration of the amino acid sequence is considered an unlikely mechanism of disease.^{12,16} The most plausible explanation, therefore, would be a change in gene expression regulation. This explanation is supported by the observation that duplication or triplication of SNCA leads to glial cytoplasmic inclusion formation in the brains of affected individuals, and that in some subjects, the clinical presentation resembles a MSA phenotype.⁴⁻⁶ A modest alteration in gene expression levels, although pathogenic in a given individual, may have escaped detection in previous SNCA expression studies of small sample size.¹⁸⁻²⁰ The identified risk variants may also alter the splicing pattern of SNCA in a pathogenic manner, or alter SNCA messenger RNA processing, or additional genetic factors may be responsible for the different manners of synuclein accumulation in PD and MSA.

How do the results of our candidate SNP association study in MSA compare with our genome-wide association study in PD? We identified significant association with the SNCA locus in both diseases.⁹ The odds ratio associated with carrying a single risk allele of the SNCA SNP rs3857059 was 1.3 in both diseases (95% CI in PD: 1.2-1.5; 95% CI in MSA: 1.1-1.6), whereas the odds ratio for homozygous carriers was 3.8 (95% CI: 2.4-5.9) in PD and 5.9 (95% CI: 3.2-10.9) in MSA.

In summary, our study has conclusively demonstrated that genetic variants in SNCA play a role in the pathogenesis of MSA, and that these genetic factors overlap with those found in PD. These data support the general notion that variability at the gene that encodes the major pathologically deposited species is a risk factor in neurological diseases involving protein deposition²¹ but highlights that often large sample sizes are required to see such an effect. Additional genetic loci undoubtedly remain to be identified in the pathogenesis of this fatal neurodegenerative disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by the Intramural Research Program of the National Institute on Aging, the National Institute on Neurological Disorders and Stroke and the Institute of Environmental Health Services, Department of Health and Human Services; project numbers Z01-AG000957-06 (S.W.S., J.R.G., J.S.S., J.B., J.D., B.J.T., S.A., R.R.Z., A.B.S.) and Z01-ES101986 (H.C.). We gratefully acknowledge support by the Medical Research Council (MRC) (H.H. G108/638 Clinician Scientist Fellowship; N.W., J.A.H.), the Michael J. Fox Foundation (H.H., C.P.R., J.A.H.), the Reta Lila Weston Institute for Neurological Studies (J.A.H., T.R., A.L., J.H.), the Sarah Matheson Trust for Multiple System Atrophy (H.H., T.R., J.H.), the Alzheimer Research Trust (J.A.H.), the National Organization for Rare Disorders (NORD) (H.H.), Ataxia UK (H.H.) and the Progressive Supranuclear Palsy (Europe) Association (J.A.H., T.R., J.H., A.L.). This work was performed under the auspices of the European MSA Study Group (EMSA-SG; <http://www.emsa-sg.org/>), which is supported by an EU project (QLK6-CT2000-00661). The KORA research platform (KORA: Cooperative Research in the Region of Augsburg; www.gsf.de/kORA) was initiated and financed by the GSF-National Research Centre for Environment and Health, which is funded by the German Federal Ministry of Education, Science, Research, and Technology and by the State of Bavaria (T.I.); furthermore, the study was funded by the German National Genome Network (NGFNplus; German Ministry for Education and Research, #01GS08134) (T.G., C.S., M.S.) and the Helmholtz association (alliance for mental health in an ageing society) (T.G., C.S., M.S.). DNA samples contributed by the Parkinson Institute-Istituti Clinici di Perfezionamento were from the "Human genetic bank of patients affected by PD and parkinsonisms" (<http://www.parkinson.it/dnabank.html>), which is supported by the Italian Telethon (n. GTB07001).

We thank the participants of this study. We gratefully acknowledge the Queen Square Brain Bank and the New York Brain Bank at Columbia University for providing tissue samples. Human tissue was also obtained from the National Institute of Child Health and Human Development Brain and Tissue Bank for Developmental Disorders at the University of Maryland and the Human Brain and Spinal Fluid Resource Center, Veterans Affairs West Los

Angeles Healthcare Center, which is sponsored by the NIH (National Institute of Neurological Disorders and Stroke/National Institute of Mental Health), the National Multiple Sclerosis Society, and the Department of Veteran Affairs.

References

1. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. *Arch Neurol*. 2001; 58:186–190. [PubMed: 11176955]
2. Nee LE, Gomez MR, Dambrosia J, et al. Environmental occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. *Clin Auton Res*. 1991; 1:9–13. [PubMed: 1821673]
3. Wenning GK, Wagner S, Daniel S, Quinn NP. Multiple system atrophy: sporadic or familial? *Lancet*. 1993; 342:681.
4. Fuchs J, Nilsson C, Kachergus J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. *Neurology*. 2007; 68:916–922. [PubMed: 17251522]
5. Gwinn-Hardy K, Mehta ND, Farrer M, et al. Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. *Acta Neuropathol*. 2000; 99:663–672. [PubMed: 10867800]
6. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. *Science*. 2003; 302:841. [PubMed: 14593171]
7. Hara K, Momose Y, Tokiguchi S, et al. Multiplex families with multiple system atrophy. *Arch Neurol*. 2007; 64:545–551. [PubMed: 17420317]
8. Wullner U, Abele M, Schmitz-Huebsch T, et al. Probable multiple system atrophy in a German family. *J Neurol Neurosurg Psychiatry*. 2004; 75:924–925. [PubMed: 15146018]
9. Scholz S.; Schulte, C. PD Genetics Consortium. Genome-Wide Association Study in Parkinson's Disease: identification of strong associations with SNCA and MAPT [abstract program number 90]; Presented at the annual meeting of The American Society of Human Genetics; November 13, 2008; Philadelphia, Pennsylvania.
10. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. *Clin Auton Res*. 1998; 8:359–362. [PubMed: 9869555]
11. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007; 81:559–575. [PubMed: 17701901]
12. Chen R, Forno L, DiMonte D, et al. Mutation screening in the alpha-synuclein gene in MSA. *Parkinsonism Relat Disord*. 1999; 5:S28.
13. Lincoln SJ, Ross OA, Milkovic NM, et al. Quantitative PCR-based screening of alpha-synuclein multiplication in multiple system atrophy. *Parkinsonism Relat Disord*. 2007; 13:340–342. [PubMed: 17291816]
14. Morris HR, Vaughan JR, Datta SR, et al. Multiple system atrophy/progressive supranuclear palsy: alpha-synuclein, synphilin, tau, and APOE. *Neurology*. 2000; 55:1918–1920. [PubMed: 11134398]
15. Ozawa T, Healy DG, Abou-Sleiman PM, et al. The alpha synuclein gene in multiple system atrophy. *J Neurol Neurosurg Psychiatry*. 2006; 77:464–467. [PubMed: 16543523]
16. Ozawa T, Takano H, Onodera O, et al. No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. *Neurosci Lett*. 1999; 270:110–112. [PubMed: 10462110]
17. Litvan I, Goetz CG, Jankovic J, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. *Arch Neurol*. 1997; 54:937–944. [PubMed: 9267967]
18. Langerveld AJ, Mihalko D, DeLong C, Walburn J, Ide CF. Gene expression changes in postmortem tissue from the rostral pons of multiple system atrophy patients. *Mov Disord*. 2007; 22:766–77. [PubMed: 17290454]
19. Ozawa T, Okuizumi K, Ikeuchi T, et al. Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. *Acta Neuropathol*. 2001; 102:188–190. [PubMed: 11563635]

20. Vogt IR, Lees AJ, Evert BO, et al. Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. *Exp Neurol*. 2006; 199:465–478. [PubMed: 16626704]
21. Singleton A, Myers A, Hardy J. The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. *Hum Mol Genet*. 2004; 13:123–126.

\$watermark-text

\$watermark-text

\$watermark-text




Fig. Location of the association signal at the SNCA locus on chromosome 4q22.1

Association signals are shown for all single nucleotide polymorphisms (SNPs) genotyped in (A) screening-stage samples (black circles), (B) replication-stage samples (blue circles), and (C) for combined screening- and replication-stage samples (red circles). The most associated SNPs, rs11931074 and rs3857059, lie in or near the SNCA gene, and are in complete linkage disequilibrium. The plot were generated using the SNP. plotter package within R version 2.6.1.

Table

Nine Most Significantly Associated Single Nucleotide Polymorphisms

SNP ID	Chromosome	Gene	Risk allele	Screening stage		Replication stage		Combined	
				P min (test model)	OR (95% CI) [RR vs (RP+PP)]	P recessive	OR (95% CI) [RR vs (RP+PP)]	P recessive	OR (95% CI) [RR vs (RP+PP)]
rs11931074	4q22.1	Downstream of SNCA	T	1.7E-07(recessive) ^b	5.4 (2.7-11.1)	1.6E-04 ^a	6.6 (2.15-19.93)	5.5E-12	6.2 (3.4-11.2)
rs3857059	4q22.1	SNCA	G	6.9E-04(recessive)	3.8 (1.7-8.5)	1.3E-06 ^a	9.8 (3.20-29.78)	2.1E-10	5.9 (3.2-10.9)
rs9480154	6q25.1	Downstream of PPP1R14C	A	1.6E-05(recessive) ^b	5.0 (2.2-11.2)	0.99	1.0 (0.12-8.81)	1.3E-04	3.9 (1.8-8.2)
rs2794256	6q22.31	LOC728727	T	1.7E-03(recessive)	1.7 (1.2-2.5)	0.17	1.6 (0.81-3.19)	4.0E-04	1.7 (1.3-2.4)
rs2042079	2p24.2	Intergenic	A	2.7E-03(recessive)	1.7 (1.2-2.5)	0.21	1.6 (0.77-3.18)	8.0E-04	1.7 (1.3-2.4)
rs13139027	4p16.2	Upstream of MSX1	A	2.5E-03(recessive)	3.9 (1.5-10.1)	0.53	1.5 (0.41-5.63)	1.8E-03	3.2 (1.5-6.9)
rs2515501	8p23.2	MCPHI	T	6.5E-04(recessive)	2.4 (1.4-4.1)	0.45	0.6 (0.13-2.52)	7.0E-03	1.9 (1.2-3.2)
rs2896159	7q31.2	Intergenic	T	3.0E-03(recessive)	0.7 (0.5-1.1)	0.38	1.3 (0.73-2.26)	0.43	1.3 (1.1-1.6)
rs2856336	12p13.2	ETV6	C	1.6E-08(recessive) ^b	4.6 (2.6-8.3)	0.12	---	2.4E-05	3.1 (1.8-5.5)

^aExceeded Bonferroni significance threshold in the replication stage (i.e., $0.05/10 = 0.005$).

^bExceeded Bonferroni significance threshold for multiple testing in the screening stage (i.e., $0.05/(384*5) = 2.6E-05$).

^cUnable to calculate odds ratio (OR) because of low allele frequency in cases. SNP = single nucleotide polymorphism; CI = confidence interval; R = risk allele; P = protective allele; HWE = Hardy-Weinberg equilibrium.

SHORT REPORT

Probable multiple system atrophy in a German family

U Wüllner, M Abele, T Schmitz-Huebsch, K Wilhelm, R Benecke, G Deuschl, T Klockgether

J Neurol Neurosurg Psychiatry 2004;**75**:924–925. doi: 10.1136/jnnp.2003.025155

Multiple system atrophy (MSA) is a neurodegenerative disorder of unknown aetiology. A possible underlying genetic component has not yet been identified. A family is reported with phenotypic MSA and probable autosomal dominant inheritance. The patients presented initially with either parkinsonian or cerebellar signs, and developed severe autonomic failure and typical atrophy of the brain stem and cerebellum in the course of the disease.

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder of unknown aetiology, clinically characterised by poorly levodopa responsive parkinsonism with or without cerebellar dysfunction, in combination with autonomic failure.¹ α -Synuclein positive oligodendroglial inclusions are the specific neuropathological hallmark of MSA. Like idiopathic Parkinson's disease, MSA might therefore be classified as a sporadic synucleinopathy.² While both autosomal dominant and recessive traits have been identified in Parkinson's disease, no familial cases of MSA have yet been reported. We describe a family with a phenotype typical of MSA in two successive generations.

METHODS

All family members were examined by two of us (UW and TSH), using the unified multiple system atrophy rating scale (UMSARS) and the unified Parkinson's disease rating scale (UPDRS). All had standardised autonomic testing, and magnetic resonance imaging (MRI) was undertaken in nine family members, the protocol including T1-TSE three dimensional volume datasets and T2 weighted images, as described previously.³ The two affected patients underwent additional single photon emission computed tomography (SPECT) with ¹²³I-FP-CIT and ¹²³I-IBZM.

RESULTS

The family comes from northern Germany. There are 14 living members in three generations, without any history of consanguinity (fig 1).

I₁ first presented at age 68 years with akinetic parkinsonism which responded well to levodopa treatment for approximately eight years. Urinary incontinence and orthostatic dysfunction developed within two years, and ataxia of gait and stance within six years after the initial diagnosis. On examination (aged 77), she showed no cognitive impairment. Ataxia of gait and stance was severe and she was unable to walk unaided. She had a smooth expressionless face, severe dysarthria, upper and lower limb ataxia, symmetrical brisk tendon reflexes, and cogwheel rigidity, but no plantar responses (UMSARS scores: I (activities of daily living), 35; II (motor examination), 43; UPDRS III, 39). Blood pressure was 140/100 mm Hg recumbent and 100/60 mm Hg upright, the change of posture producing giddiness. MRI showed severe brain stem and cerebellar atrophy with a hot cross bun

sign (fig 2). Only moderate changes were present in the putamen.

II₁ first presented at age 46 years with ataxia of gait. A partial (urge) incontinence, orthostatic dysfunction, and mild right sided parkinsonism developed within two years after the occurrence of ataxia. On examination (age 49), she showed no cognitive impairment. She had mild ataxia of gait and stance and mild upper and lower limb ataxia, moderate dysarthria, symmetrical brisk tendon reflexes, and mild cogwheel rigidity of the right arm, but no plantar responses (UMSARS scores: I (activities of daily living), 11; II (motor examination), 18; UPDRS III, 19). Blood pressure was 130/90 mm Hg recumbent and 100/90 mm Hg upright. MRI showed predominant cerebellar and moderate brain stem atrophy with a hot cross bun sign (fig 2).

Subjects II₂₋₄ (aged 48–55) all had completely normal neurological examinations except for a minimal ataxia of gait in II₂ when walking in tandem with eyes closed, and a corresponding discrete atrophy of the upper vermis on MRI (not shown).

Subjects III₁₋₃ (aged 21–28), the three children of II₁, had completely normal neurological examinations and MRIs (not shown).

I₁ and II₁ underwent SPECT with ¹²³I-FP-CIT and ¹²³I-IBZM. Both showed an asymmetrical massive reduction of the presynaptic dopamine transporter and a moderate loss of dopamine D2 receptors (data not shown). Extensive laboratory testing was undertaken in I₁ and II₁: all routine variables, including caeruloplasmin and urine copper, were within the normal range; CSF samples were normal, without oligoclonal bands. Genetic testing excluded spinocerebellar ataxia (SCA) types 1–3, 6, 7, and 17 in I₁ and II₁.

DISCUSSION

This is the first description of a family with the clinical phenotype of probable MSA, corresponding morphological changes on MRI, and a probable autosomal dominant inheritance. In 1964, before the recognition of MSA as a disease entity, Lewis described a family with orthostatic hypotension as the leading symptom.⁴ However, while two family members had ataxia and parkinsonism and might have fulfilled the current criteria of probable or possible MSA, a common feature in that family seemed to be prominent amyotrophy and rather slow disease progression, with a disease duration of more than 30 years in one case.⁴ In addition, the predominant symptom in two cases was diarrhoea, which could point to coeliac disease. Diarrhoea, autonomic failure, and cerebellar degeneration are also observed in hereditary neuronal nuclear inclusion disease (NIID), even though at least in some cases NIID symptoms may start in childhood.⁵

Although a multigenic aetiology of MSA is often suspected, the evidence for a genetic component is rather weak, and families with MSA have not been described up to now. A family with necropsy proven Parkinson's disease and a family with necropsy proven MSA was reported by Shimo *et al.*,⁶ but the significance of that combination remains unclear. The




Figure 1 Patient pedigree.




Figure 2 T2 weighted horizontal magnetic resonance images at the level of the basal ganglia (left) and the brain stem (right): bottom, I₁; top, II₁. Note the atrophy of the cerebellar peduncle with gliosis and the hot cross bun sign in the brain stem (arrowheads). Only moderate gliosis is present at the outer rim of the putamen (arrows).

probability that the cases encountered occurred by chance alone is rather low. The standardised prevalence rates of MSA are estimated to be 4 or 5 in 100 000.⁷ Thus the probability of finding two patients with probable MSA in a family of 14 members by chance alone is as low as 0.0006. A genetic predisposition for MSA was suggested by an epidemiological study by Nee *et al*, who reported a higher frequency of symptoms and neurological diseases in first degree relatives of 60 MSA cases than in controls (23% in MSA cases *v* 10% in controls).⁸ Although a small study reported an association between MSA and a mutant allele of the CYP11D6 gene, a subsequent analysis did not find an association between MSA and genetic variants of the genes coding for CYP11D6, apoE, the receptor for IGF-1, ciliary neurotrophic factor (CNTF), the H5 pore region of the human homologue of the weaver mouse gene, or HLA-A32.⁹⁻¹⁰ Also, no mutations were

identified in the coding region of the α -synuclein gene.¹¹⁻¹³ Neither CAG trinucleotide repeat expansions of spinocerebellar ataxia types 1-3, 6-8, and 12, nor frataxin mutations were found in 20 patients with possible or probable MSA.¹² In our family none of the known SCA mutations was found, although the marked difference in age at disease onset in the two affected family members (*anticipation*) could point to an as yet unidentified trinucleotide repeat disorder.

Identification of the present family suggests that MSA—although considered a sporadic disease—may be inherited in rare instances. As with Parkinson's disease, genetic analysis of larger families might provide clues to the suspected genetic basis of MSA.

ACKNOWLEDGEMENTS

This study was supported by the Kompetenznetz Parkinson (01G19901), NGFN (01GS0115, NV-SO2T9), and the BONFOR Program of the University Bonn

Authors' affiliations

U Wüllner, M Abele, T Schmitz-Huebsch, T Klockgether, Department of Neurology, UKB, Sigmund Freud Strasse, Bonn, Germany
K Wilhelm, Department of Radiology, UKB, Bonn
R Benecke, Department of Neurology, UKR, Rostock, Germany
G Deuschl, Department of Neurology, UKK, Kiel, Germany

Competing interests: none declared

Correspondence to: PD Dr med U Wüllner, Department of Neurology, University Bonn (UKB), Sigmund Freud Str 25, D-53105 Bonn, Germany; wuellner@uni-bonn.de

Received 15 August 2003

In revised form 6 October 2003

Accepted 7 October 2003

REFERENCES

- Gilman S, Low PA, Quinn N, *et al*. Consensus statement on the diagnosis of multiple system atrophy. *J Auton Nerv Syst* 1998;**74**:189-92.
- Goedert M. Alpha-synuclein and neurodegenerative diseases. *Nat Rev Neurosci* 2001;**2**:492-501.
- Specht K, Minnerop M, Abele M, *et al*. In vivo voxel-based morphometry (VBM) in multiple system atrophy of cerebellar type (MSA-C). *Arch Neurol* 2003;**60**:1413-35.
- Lewis P. Familial orthostatic hypotension. *Brain* 1964;**87**:719-28.
- Zannoli R, Gilman S, Rossi S, *et al*. Hereditary neuronal intranuclear inclusion disease with autonomic failure and cerebellar degeneration. *Arch Neurol* 2002;**59**:1319-26.
- Shimo Y, Takanashi M, Ohta S, *et al*. A 56-year-old woman with parkinsonism, whose mother had Parkinson's disease. *No To Shinkei* 2001;**53**:495-505.
- Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. *Lancet* 1999;**354**:1771-5.
- Nee LE, Gomez MR, Dambrosia J, *et al*. Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. *Clin Auton Res* 1991;**1**:9-13.
- Iwahashi K, Miyatake R, Tsunooka Y, *et al*. A novel cytochrome P45011D6 (CYP11D6) mutant gene associated with multiple system atrophy. *J Neurol Neurosurg Psychiatry* 1995;**58**:263-4.
- Bandmann O, Sweeney MG, Daniel SE, *et al*. Multiple-system atrophy is genetically distinct from identified inherited causes of spino-cerebellar degeneration. *Neurology* 1997;**49**:1598-604.
- Ozawa T, Takano H, Onodera O, *et al*. No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. *Neurosci Lett* 1999;**270**:110-12.
- Morris HR, Vaughan JR, Datta SR, *et al*. Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE. *Neurology* 2000;**55**:1918-20.
- Schals L, Szymanski S, Peters S, *et al*. Genetic background of apparently idiopathic sporadic cerebellar ataxia. *Hum Genet* 2000;**107**:132-7.